

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Cohort profile: the Johns Hopkins COVID Long Study (JHCLS), a United States Nationwide Prospective Cohort Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-077742
Article Type:	Cohort profile
Date Submitted by the Author:	13-Jul-2023
Complete List of Authors:	Wentz, Eryka; Johns Hopkins University Bloomberg School of Public Health, Epidemiology Ni, Zhanmo; Johns Hopkins School of Medicine, Oncology Yenokyan, Karine; Johns Hopkins University Bloomberg School of Public Health, Epidemiology Coggiano, Candelaria; Johns Hopkins University Bloomberg School of Public Health, Epidemiology Pahwa, Jessica; Johns Hopkins University Bloomberg School of Public Health, Epidemiology Kammerling, Thea; Johns Hopkins University Bloomberg School of Public Health, Epidemiology Xiao, Pu; Johns Hopkins University Whiting School of Engineering, Data Science Duggal, Priya; Johns Hopkins University Bloomberg School of Public Health, Epidemiology Lau, Bryan; Johns Hopkins University Bloomberg School of Public Health, General Epidemiology and Methodology Mehta, Shruti; Johns Hopkins University Bloomberg School of Public Health, Epidemiology
Keywords:	COVID-19, SARS-CoV-2, INFECTIOUS DISEASES, Chronic Disease, EPIDEMIOLOGIC STUDIES

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

## Cohort profile: the Johns Hopkins COVID Long Study (JHCLS), a United States Nationwide Prospective Cohort Study

Eryka Wentz, MA, [ewentz1@jhu.edu](mailto:ewentz1@jhu.edu)  
Zhanmo Ni, MHS, [zni4@jhu.edu](mailto:zni4@jhu.edu)  
Karine Yenokyan, PhD, [kyenoky1@jhu.edu](mailto:kyenoky1@jhu.edu)  
Candelaria Coggiano, MD, [candelaria.coggiano@jhmi.edu](mailto:candelaria.coggiano@jhmi.edu)  
Jessica Pahwa, MPH, [jpahwa1@jh.edu](mailto:jpahwa1@jh.edu)  
Thea Kammerling, BA, [tkammer1@jhu.edu](mailto:tkammer1@jhu.edu)  
Pu Xiao, BS, [pxiao3@jhu.edu](mailto:pxiao3@jhu.edu)  
Priya Duggal, PhD, [pduggal@jhu.edu](mailto:pduggal@jhu.edu)  
Bryan Lau, PhD, [blau1@jhu.edu](mailto:blau1@jhu.edu)  
Shruti H. Mehta, PhD, [smehta@jhu.edu](mailto:smehta@jhu.edu)

Corresponding author: Eryka Wentz, 615 N. Wolfe Street, Baltimore, MD 21205, [ewentz1@jhu.edu](mailto:ewentz1@jhu.edu), (410) 834-1603

Keywords: COVID-19, SARS-CoV-2, Infectious Diseases, Chronic Disease, Epidemiologic Studies

Word count: 4,028

### ABSTRACT

**Purpose** COVID-19 disease continues to affect millions of individuals worldwide, both in the short and long term. The post-acute complications of SARS-CoV-2 infection, referred to as long COVID, result in diverse symptoms affecting multiple organ systems. Little is known regarding how the symptoms associated with long COVID progress and resolve over time. The Johns Hopkins COVID Long Study aims to prospectively examine the short- and long-term consequences of COVID-19 disease in individuals both with and without a history of SARS-CoV-2 infection using self-reported data collected in an online survey.

**Participants** Sixteen thousand, seven hundred sixty-four adults with a history of SARS-CoV-2 infection and 799 adults without a history of SARS-CoV-2 infection who completed an online baseline survey.

**Findings to date** This cohort profile describes the baseline characteristics of the Johns Hopkins COVID Long Study. Among 16,764 participants with a history of SARS-CoV-2 infection and defined long COVID status, 75% reported a good or excellent health status prior to infection, 99% reported experiencing at least one COVID-19 symptom during the acute phase of infection, 9.9% reported a hospitalization, and 63% were defined as having long COVID using the WHO definition.

**Future plans** Analysis of longitudinal data will be used to investigate the progression and resolution of long COVID symptoms over time.

## ARTICLE SUMMARY

### Strengths and limitations of this study

- The Johns Hopkins COVID Long Study (JHCLS) is a large, online, prospective cohort study of adults that collects comprehensive clinical and behavioral data on participants with and without a history of SARS-CoV-2 infection at baseline with an option to participate in longitudinal follow-up every 3-6 months.
- Detailed clinical data are collected on COVID-19 diagnosis and treatment, health history, and pre-existing health conditions, in addition to validated measurements on physical, mental, and cognitive limitations.
- The JHCLS is comprised of participants from 53 United States and territories and includes individuals aged 19-96 years.
- Because SARS-CoV-2 tests are not always accessible, eligibility requirements include either a self-reported positive SARS-CoV-2 test or symptoms of COVID-19.
- There may be selection and recall bias due to the increased likelihood of participation by individuals with long COVID and self-reported clinical data; however, the JHCLS is comprised of a subset of individuals who enrolled within four weeks of their initial SARS-CoV-2 infection and had not yet developed long COVID.

## INTRODUCTION

Since its first emergence in 2019, COVID-19 has greatly affected the health and well-being of millions of people worldwide.(1,2) Both acute and persistent post-infection complications have been reported by patients(3) and COVID-19 is now recognized as a multi-organ disease.(4) The World Health Organization (WHO) defines persistent post-infection complications, referred to as long COVID, as new or continuing symptoms three months after initial illness that last at least two months and cannot be explained otherwise.(5) Despite recent studies suggesting that long COVID may occur in 10-55% of individuals exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),(6–8) the exact incidence remains unknown. In addition, there is uncertainty in the pathophysiology and symptomatology of long COVID.(9,10) With the elevated burden of long-term effects of COVID-19 worldwide, it is important to understand the full range of associated symptoms and understand the long-term outcomes.(2) Moreover, the large number of individuals requiring continued medical care will pose an economic burden on our health care system.(10)

Similar to other infections, SARS-CoV-2 is associated with post-acute infection syndromes resulting in a variety of symptoms.(11) Some of the core symptoms associated with long COVID are common to other post-acute infection syndromes as well, including but not limited to fatigue, exertion intolerance, and neurocognitive impairment.(11) Despite our general knowledge of the occurrence of post-acute infection syndromes, it is largely understudied. Cohort studies composed of those who have had SARS-CoV-2 and those who have not (i.e., control population) are critical to understanding the gaps in our knowledge of long COVID and post-acute infections in general.

The presentation of those with long COVID is often marked with multiple diverse symptoms affecting multiple organs; each individual may have their own unique clinical presentation.(12) Though age is a major risk factor in COVID-19 related mortality, and despite a preponderance of long COVID among those aged 40 - 60 years, long COVID is reported across the age spectrum.(13) Similarly, long COVID is reported by persons of all genders, race/ethnicities, and those with and without pre-existing comorbidities.(13,14) Hence, it is essential that research both identifies and characterizes the main clinical and epidemiological features associated with long COVID, including potential targets for intervention.

For these reasons, the Johns Hopkins COVID Long Study (JHCLS) was established to prospectively examine the short- and long-term consequences of COVID-19 over a 3-year follow-up period. The overall objectives of the JHCLS are to (1) characterize the spectrum of long-term sequelae of SARS-CoV-2 infection; (2) identify individuals at risk for long-term


1  
2  
3 sequelae; and (3) characterize the physical and mental health disability associated with long  
4 COVID. To meet study objectives, the cohort includes participants with and without a history of  
5 SARS-CoV-2 infection. This cohort profile describes baseline demographic and clinical  
6 characteristics of United States (U.S.) participants enrolled in the JHCLS.  
7  
8  
9  
10

## 11 **COHORT DESCRIPTION**

### 12 **Study design and participants**

13  
14  
15  
16 The JHCLS launched for participants with a self-reported history of SARS-CoV-2 infection  
17 on February 2, 2021, and expanded to include participants without a history of SARS-CoV-2  
18 infection on March 2, 2022. All consenting participants are asked to complete a one-time, short  
19 online baseline survey with the option to remain anonymous. At the end of the baseline survey,  
20 participants are asked if they would like to be contacted for future COVID-19 studies, such as  
21 enrollment into longitudinal follow-up. If they respond yes, they are asked to provide contact  
22 information and are contacted by email or phone 3-6 months later with information about  
23 participating in longitudinal follow-up. If they subsequently consent to participate in longitudinal  
24 follow-up, they are emailed a follow-up survey every 3-6 months.  
25  
26  
27  
28  
29

30 As of February 14, 2023, 20,319 participants with a self-reported history of SARS-CoV-2  
31 infection and 1,041 participants without a history of SARS-CoV-2 infection consented to  
32 participate in the JHCLS (Figure 1). Of the 20,319 participants with a history of infection, 15,798  
33 (78%) completed the baseline survey and 12,170 (60%) consented to be contacted for future  
34 studies. Of these, 6,327 have enrolled in longitudinal follow-up and completed their first follow-  
35 up survey. Of the 1,041 participants without a history of infection, 799 (77%) completed the  
36 baseline survey and 501 (48%) consented to be contacted for future studies. Of these, 278 have  
37 enrolled in longitudinal follow-up and completed their first follow-up survey (Figure 1). At each  
38 round of follow-up, participants without a history of infection are asked if they have experienced  
39 COVID-19 symptoms or tested positive for SARS-CoV-2 since their last survey completion. If  
40 they respond yes, they are transferred to the survey for participants with a history of infection.  
41 As of February 14, 2023, 46 of the 278 participants (17%) who completed their first round of  
42 longitudinal follow-up have self-reported either a positive SARS-CoV-2 test or symptoms of  
43 COVID-19 since their last survey completion. The median survey completion time for the  
44 baseline survey is currently 20 minutes and the median time for the first follow-up survey is 24  
45 minutes.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Figure 1** Flow diagram showing United States recruitment into the Johns Hopkins COVID Long Study

\*Participants who agree to be contacted for future studies are asked to consider joining the longitudinal follow-up cohort 3-6 months after they complete the baseline survey. As of this report, not everyone who has agreed to be contacted for future studies has been invited to join the longitudinal follow-up cohort yet.

## Recruitment

Participants are recruited into the JHCLS using several mechanisms: social media posts, Facebook ad campaigns, direct messaging (e.g., emails to health departments, religious institutions, community organizations, etc.), word of mouth, and participation in a recruitment registry. For social media recruitment, researchers utilize study-owned and operated Instagram, Facebook, and Twitter accounts. In addition, the team partnered with the Audience Development Team at the Johns Hopkins Bloomberg School of Public Health (BSPH) Communications Department to develop targeted Facebook ad campaigns. The study ran three Facebook ad campaigns, each targeting a neighborhood in the U.S. with high SARS-CoV-2 case counts. Two campaigns ran in April 2021, the first targeting neighborhoods in Detroit, Michigan, and the second targeting neighborhoods in Fayetteville and Hope Mills, North



1  
2  
3 Carolina, and South Fulton and Alpharetta, Georgia. The final campaign ran in July 2021 and  
4 targeted neighborhoods in Houston and San Antonio, Texas, Miami and Jacksonville, Florida,  
5 and Los Angeles, California.  
6  
7

8 The study team also partners with the Johns Hopkins Opportunities for Participant  
9 Engagement (HOPE) Registry. The HOPE Registry (<http://johnshopkinshope.org/>) is a  
10 recruitment registry designed to connect individuals with teams conducting COVID-19 research  
11 studies at Johns Hopkins University. The JHCLS was officially enrolled into the HOPE Registry  
12 in April 2021.  
13  
14  
15

### 16 17 **Participant eligibility**

18 The JHCLS was approved and determined to be exempt by the Institutional Review Board  
19 (IRB) at the BSPH on January 8, 2021.  
20

21 To be eligible to participate in the overall study, participants must be at least 18 years of  
22 age. Additionally, to be eligible to complete the survey for participants with a history of SARS-  
23 CoV-2 infection, participants must self-report at least one positive SARS-CoV-2 test or  
24 symptoms of COVID-19. At the start of the baseline survey, eligible participants are provided  
25 with a short, informed consent script that details the purpose of the study and provides details  
26 on participation. In order to protect the confidentiality of participants, participants are assigned a  
27 unique study identifier number and data are collected anonymously.  
28  
29  
30  
31  
32  
33

### 34 **Study procedures**

35 The JHCLS baseline survey is self-administered and collects data across nine domains:  
36 SARS-CoV-2 testing and COVID-19 symptoms, vaccines and SARS-CoV-2 re-infection,  
37 COVID-19 treatments and hospitalizations, pre-existing comorbidities, physical limitations and  
38 exercise, sleep quality, mental fatigue, anxiety, and demographics (Table 1). Data from these  
39 same domains are collected during longitudinal follow-up as well. All data are collected in  
40 REDCap, a HIPAA-compliant, secure web application designed to build and manage online  
41 surveys and databases.<sup>(15,16)</sup> Most survey questions were adapted from validated measures  
42 and assessments. However, certain questions were self-designed for the purpose of meeting  
43 study objectives.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

<b>Domain</b>	<b>Questionnaire</b>	<b>Variable Description</b>	<b>Validation</b>	<b>Scoring</b>
SARS-CoV-2 Testing and COVID-19 Symptoms	Self-designed	General health before COVID-19 illness (population with history of SARS-CoV-2 infection) or COVID-19 pandemic (population without history of SARS-CoV-2 infection), SARS-CoV-2 testing (number of times, result, exposure, test type, month/year of first positive test), month/year of initial symptom onset, symptoms experienced during initial illness, new/continuing symptoms experienced after initial illness, impact of each symptom on daily activities, self-reported recovery compared to before COVID-19 illness (population with history of SARS-CoV-2 infection) or COVID-19 pandemic (population without history of SARS-CoV-2 infection)	N/A	Categorical responses
Vaccines and SARS-CoV-2 Re-infection	Self-designed	Flu vaccine uptake, COVID-19 vaccine uptake (number of doses, series type, month/year per dose), SARS-CoV-2 antibody testing (month/year of testing, result), COVID-19 treatment trials, COVID-19 re-infection (number of times, exposure, test type, month/year of each positive test, month/year of each symptom onset), comparison of first re-infection to initial infection	N/A	Categorical responses
COVID-19 Treatments and Hospitalizations	Self-designed	Treatments for COVID-19, treatments for new/continuing COVID-19 symptoms, hospitalizations (number of days, severity), health care utilization (pre-COVID-19 illness and current), health seeking behavior to treat symptoms	N/A	Categorical responses
Comorbidities	Self-designed	Self-reported current health status, pre-existing health conditions, cancer diagnosis (type, diagnosis timeframe, treatments), height, weight, current stress level, stress level before the COVID-19 pandemic	N/A	Categorical responses

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

<b>Table 1</b> Continued				
<b>Domain</b>	<b>Questionnaire</b>	<b>Variable Description</b>	<b>Validation</b>	<b>Scoring</b>
Limitations and Exercise	Baltimore Longitudinal Study of Aging(17,18)	Overall physical limitations before COVID-19 illness (population with history of SARS-CoV-2 infection) or COVID-19 pandemic (population without history of SARS-CoV-2 infection), difficulty walking a quarter of a mile/one mile, difficulty walking up 10 steps/20 steps, difficulty with performing light housework/heavy housework, difficulty level (if difficulty reported), level of ease (if no difficulty reported), indicator for incident/prevalent disability	N/A	<p><u>Mobility disability</u>: Any level of difficulty walking a quarter of a mile</p> <p><u>Instrumental activities of daily living disability</u>: Any level of difficulty with light housework</p>
	Godin-Shephard Leisure-Time Physical Activity Questionnaire(19–21)	Number of times in a typical week doing strenuous, moderate, and mild intensity exercise for more than 15 minutes before and after COVID-19 illness (population with history of SARS-CoV-2 infection) or COVID-19 pandemic (population without history of SARS-CoV-2 infection)	<p>Validated in population of healthy adults</p> <p>Test-retest reliability: 0.94 for strenuous exercise, 0.46 for moderate exercise, and 0.48 for light exercise</p>	<p>1) Multiply number of times per week per category by Metabolic Equivalent of Task factor (3 for light, 5 for moderate, 9 for strenuous)</p> <p>2) Sum scores for total leisure time activity score</p> <ul style="list-style-type: none"> <li>• <math>\geq 24</math>: active lifestyle</li> <li>• 14-23: moderately active lifestyle</li> <li>• <math>&lt; 14</math>: sedentary lifestyle</li> </ul>
Sleep Quality	AIDS Linked to the IntraVenous Experience (ALIVE) Study(22)	Total hours slept in typical 24-hour period, overall sleep quality during last four weeks, insomnia (difficulty falling/staying asleep)	N/A	Categorical responses
	Idiopathic Hypersomnia Severity Scale(23,24)	Four indicators of hypersomnia (assessment of sleep adequacy, difficulty waking up, length of time to feel fully functioning upon waking, struggling to stay awake during the day)	<p>Validated in patients experiencing idiopathic hypersomnia</p> <p>High internal consistency (Cronbach <math>\alpha=.89</math>) and good content validity</p>	<p>1) Each item is assigned a score (0-3 or 0-4)</p> <p>2) Sum scores for a total of 0-14</p> <p>Higher scores represent more severe/frequent symptoms of idiopathic hypersomnia</p>

**Table 1** Continued

Domain	Questionnaire	Variable Description	Validation	Scoring
Cognition	Wood Mental Fatigue Inventory (WMFI)(25)	Nine indicators of mental fatigue over last two weeks (confusion, mixed thoughts, poor concentration, difficulty with decision making, memory problems, issues taking things in, slow thoughts, muzzy head, issues finding words)	Validated in patients with ME/CFS  High internal consistency (Cronbach $\alpha$ =.93) and good test-retest reliability (Pearson's $r$ = 0.887)	1) Each item is assigned a score from 0-4  2) Sum scores for total of 0-36  Higher scores indicate greater levels of mental fatigue
Anxiety	Generalized Anxiety Disorder-7 (GAD-7)(26)	Seven indicators of anxiety over last two weeks (feeling anxious, not able to control worrying, worrying about different things, trouble relaxing, restlessness, irritability, feeling afraid)	Validated in general population  High internal consistency (Cronbach $\alpha$ =.92)  Good criterion, construct, factorial, and procedural validity	1) Each item is assigned a score from 0-3  2) Sum scores for total of 0-21  <ul style="list-style-type: none"> <li>• 0-4: no anxiety disorder</li> <li>• 5-9: mild anxiety disorder</li> <li>• 10-14: moderate anxiety disorder</li> <li>• <math>\geq</math>15: severe anxiety disorder</li> </ul>
Demographics	Self-designed	Work activities prior to the COVID-19 pandemic, primary occupation, household income in 2019, number of dependents	N/A	Categorical responses

### SARS-CoV-2 Testing and COVID-19 Symptoms

To obtain data on COVID-19 history, diagnosis, and symptoms, researchers self-designed questions to assess overall health status prior to initial COVID-19 illness, history of SARS-CoV-2 testing and results, initial symptom onset date, symptoms experienced during the acute phase of COVID-19, new/continuing symptoms experienced after the acute phase of COVID-19, impact of each reported symptom on daily activities, and self-reported recovery from COVID-19 illness (Table 1). Participants without a history of infection are asked about health status prior to the COVID-19 pandemic, symptoms experienced in reference to overall general health, and self-reported recovery from the effects of the COVID-19 pandemic.

### Vaccines and SARS-CoV-2 Re-infection

To collect data on vaccination and SARS-CoV-2 re-infection, researchers self-designed questions related to flu vaccination uptake, COVID-19 vaccination uptake, SARS-CoV-2 antibody testing, participation in COVID-19 treatment trials, SARS-CoV-2 re-infection, and self-reported comparison of COVID-19 symptoms experienced during the first re-infection compared to initial illness (Table 1). Participants without a history of infection are asked questions related to flu and COVID-19 vaccination uptake.

### Treatments and Hospitalizations

Researchers self-designed questions to obtain data on medications used to treat initial COVID-19 illness, medications used to treat new/continuing symptoms post-initial COVID-19 illness, COVID-19 related hospitalizations, health care utilization, and health seeking behavior to treat symptoms (Table 1). In this section, participants without a history of infection are asked about overall health care utilization.

### Pre-existing Comorbidities

In order to obtain data on pre-existing health status and comorbidities, researchers self-designed questions to capture current health status, pre-existing health conditions, cancer diagnosis, height, weight, current stress level, and stress level prior to the COVID-19 pandemic (Table 1).

### Physical Limitations & Exercise

To assess physical limitations and exercise, researchers utilized questions adapted from the Baltimore Longitudinal Study of Aging and the Godin-Shephard Leisure-Time Physical Activity Questionnaire (Table 1).

1  
2  
3 The Baltimore Longitudinal Study of Aging (BLSA) is a longitudinal study of healthy adults  
4 with the aim of understanding how adults adjust to the aging process, including adjustments in  
5 physical activity.(17,18) During the baseline survey, participants are asked a series of questions  
6 to assess difficulty and level of difficulty in the following domains: mobility (walking a quarter  
7 mile/one mile and going up 10 steps/20 steps) and instrumental activities of daily living (IADL)  
8 (light and heavy housework). If a participant reports experiencing difficulty in the domain, they  
9 are asked to report the level of difficulty (a little, some, a lot, or unable to do); conversely, if they  
10 do not report difficulty, they are asked to report the level of ease (very easy, somewhat easy, or  
11 not so easy).(17,18) Participants who report difficulty are also asked if they experienced the  
12 difficulty prior to their COVID-19 illness. Participants without a history of infection are asked if  
13 they experienced the difficulty prior to the COVID-19 pandemic. For mobility, if a participant  
14 reports any level of difficulty walking a quarter of a mile, they are considered to have a mobility  
15 disability. For IADL, if a participant reports any level of difficulty with light housework, they are  
16 considered to have an IADL disability.

17  
18 The Godin-Shephard Leisure-Time Physical Activity Questionnaire (GSLTPAQ) was  
19 validated for use in healthy adults by measuring the correlation between objective measures of  
20 physical condition, maximum oxygen intake during exercise ( $V_{O_2}$  max) and body fat percentile,  
21 and subjective measures of total leisure time physical activity.(19–21) The questionnaire was  
22 found to have a test-retest reliability of 0.94, 0.46, and 0.48 for strenuous, moderate, and light  
23 intensity exercise, respectively, with the highest correlation shown between  $V_{O_2}$  max and  
24 strenuous intensity exercise (Pearson's  $r = 0.38$ ) and body fat percentile and strenuous intensity  
25 exercise (Pearson's  $r = 0.21$ ).<sup>(20)</sup>

26  
27 During the baseline survey, participants are asked to report the number of times on average  
28 they participate in mild, moderate, and strenuous intensity exercise for longer than 15 minutes  
29 during a typical week. The number of times per week is multiplied by the corresponding  
30 Metabolic Equivalent of Task (MET) factor (3, 5, and 9 for mild, moderate, and strenuous  
31 intensity exercise, respectively) and summed for a total leisure activity score.(19,20) A score of  
32  $\geq 24$  indicates an active lifestyle, a score of 14-23 indicates a moderately active lifestyle, and a  
33 score of  $< 14$  indicates an insufficiently active/sedentary lifestyle.(19) Participants with a history  
34 of infection are asked to report the number of times they exercised in each category before and  
35 after their COVID-19 illness; participants without a history of infection are asked in reference to  
36 before and after the COVID-19 pandemic.

## 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 Sleep Quality

1  
2  
3 Sleep quality is assessed using questions adapted from the AIDS Linked to the IntraVenous  
4 Experience (ALIVE) Study and the Idiopathic Hypersomnia Severity Scale (Table 1). The ALIVE  
5 study is a prospective cohort study designed to characterize the incidence and natural history of  
6 HIV infection among injection drug users in Baltimore, MD.(22) Participants are asked how often  
7 they experience a list of five items related to sleep quality over the past four weeks. For each  
8 item, participants respond based on the following scale: 1 (all of the time), 2 (most of the time),  
9 3 (a good bit of the time), 4 (some of the time), 5 (a little bit of the time), or 6 (none of the time).  
10  
11  
12  
13

14 The Idiopathic Hypersomnia Severity Scale (IHHS) was validated for use in patients  
15 experiencing three major symptoms of idiopathic hypersomnia: excessive daytime sleepiness,  
16 prolonged nighttime sleep, and sleep inertia, and was found to have high internal consistency  
17 (Cronbach  $\alpha = .89$ ) and good content validity.(23,24) The scale consists of 14 items and each  
18 item is scored separately and then summed together for a total score ranging from 0-50. Higher  
19 scores represent more severe/frequent symptoms of idiopathic hypersomnia.(23,24) For the  
20 purpose of the JHCLS, researchers utilized four questions from the IHHS for a range of scores  
21 from 0-14.  
22  
23  
24  
25  
26  
27

## 28 Mental Fatigue

29 Mental fatigue is assessed using the Wood Mental Fatigue Inventory (WMFI) (Table 1). The  
30 WMFI has been validated for use in patients with Myalgic Encephalomyelitis/Chronic Fatigue  
31 Syndrome (ME/CFS) and was found to have high internal consistency (Cronbach  $\alpha = .93$ ) and  
32 good test-retest reliability (Pearson's  $r = 0.887$ ). (25) Participants are asked how much they have  
33 been bothered by a list of nine items over the past two weeks. Each item is scored on the  
34 following scale: 0 (not at all), 1 (a little), 2 (somewhat), 3 (quite a lot), or 4 (very much). At the  
35 end of the assessment, the scores are summed together for a range of 0-36. Higher scores  
36 indicate greater levels of mental fatigue.(25)  
37  
38  
39  
40  
41  
42

## 43 Anxiety

44 To assess anxiety, researchers utilize the Generalized Anxiety Disorder-7 (GAD-7) (Table  
45 1). The GAD-7 has been validated for use in the general population and was found to have both  
46 high internal consistency (Cronbach  $\alpha = .92$ ) and good criterion, construct, factorial, and  
47 procedural validity.(26) Participants are asked how often they have been bothered by a list of  
48 seven items over the past two weeks. For each item, participants are scored based on the  
49 following scale: 0 (not at all), 1 (several days), 2 (more than half the days), or 3 (nearly every  
50 day). At the end of the assessment, the scores are summed together for a range of 0-21. A  
51 score of 0-4 indicates no anxiety disorder, a score of 5-9 indicates a mild anxiety disorder, a  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 score of 10-14 indicates a moderate anxiety disorder, and a score of  $\geq 15$  indicates a severe  
4 anxiety disorder.(26)  
5  
6

## 7 Demographics

8  
9 Researchers self-designed survey questions to obtain demographic information, including  
10 gender, race/ethnicity, country of residence, year of birth, educational attainment, work activities  
11 prior to the COVID-19 pandemic, primary occupation, total household income, and total number  
12 of dependents.  
13  
14  
15

## 16 Patient and public involvement

17  
18 There was no patient or public involvement in the design, conduct, reporting, or  
19 dissemination plans of our research. However, patient feedback is routinely discussed and  
20 considered. Specifically, patients are encouraged to reach out to study team members with  
21 suggestions on ways to improve the survey and the survey has been adjusted several times  
22 based on patient suggestions. In addition, study findings are regularly disseminated to patients  
23 via quarterly study newsletters posted on the study website ([www.covid-long.com](http://www.covid-long.com)).  
24  
25  
26  
27  
28

## 29 Baseline characteristics of JHCLS participants

30  
31 Among 16,764 participants with a history of SARS-CoV-2 infection and defined long COVID  
32 status, the median age was 43 years, 84% were female, 88% self-reported white race, and  
33 8.0% self-reported Hispanic/Latino ethnicity (Table 2). In terms of socioeconomic status, 70% of  
34 participants self-reported a bachelor's degree or higher and 72% self-reported an annual  
35 household income of greater than or equal to \$50,000. A diverse array of self-reported pre-  
36 existing comorbid conditions were reported, including hypertension (15%),  
37 depression/anxiety/other mental health conditions (35%), asthma/reactive airway  
38 disease/chronic lung disease (16%), and autoimmune disorders (9.6%) (Table 3). In addition,  
39 the majority of participants (65%) were classified as overweight/obese based on a calculated  
40 BMI of  $\geq 25$ .  
41  
42  
43  
44  
45

46  
47 Prior to COVID-19 illness, 75% of participants reported very good/excellent health status  
48 and 8.2% of participants reported fair/poor health status (Table 3). During the acute phase of  
49 COVID-19 illness, 99% of participants reported experiencing at least one symptom. Of those,  
50 90% reported cardiopulmonary symptoms (e.g., new/worsening cough, shortness of breath,  
51 rapid heart rate), 89% reported systemic symptoms (e.g., fatigue, muscle weakness, fever),  
52 85% reported neuropsychiatric symptoms (e.g., headache, dizziness, neuropathy), and 55%  
53 reported gastrointestinal symptoms (e.g., vomiting, diarrhea, lack of appetite). Overall, 9.9% of  
54  
55  
56  
57  
58  
59  
60



participants self-reported being hospitalized for their COVID-19 illness and 63% were defined as having long COVID based on the WHO definition.

At the time of study enrollment, 39% of participants with a history of infection reported not being vaccinated against SARS-CoV-2 compared to 56% who reported receiving at least a complete first vaccination series (Table 3). The median number of days between initial SARS-CoV-2 infection and study enrollment was 173 days. While most participants reported experiencing their initial SARS-CoV-2 infection in 2020 (56%), 29% reported being infected in 2021, and 16% reported being infected in 2022.

Similar characteristics were found in participants without a history of SARS-CoV-2 infection who completed the baseline survey. Among 799 participants, the median age was 42, 85% were female, 82% self-reported white race, and 5.9% self-reported Hispanic/Latino ethnicity (Table 2). A higher percentage of participants without a history of infection self-reported 'other' race (13% compared to 5.4%) which was largely due to a greater number self-reporting Asian/Pacific Islander/Native Hawaiian race. With regard to socioeconomic status, a higher percentage of participants without a history of infection reported a bachelor's degree or higher (84% compared to 70%) and 72% reported an annual household income of \$50,000 or more. Comparable pre-existing comorbid conditions were reported: hypertension (13%), depression/anxiety/other mental health conditions (36%), asthma/reactive airway disease/chronic lung disease (12%), and autoimmune disorders (8.1%) (Table 3). Based on calculated BMI, a slightly higher percentage of participants without a history of infection were classified as having a normal BMI (43% compared to 34%).

Of participants without a history of SARS-CoV-2 infection, 75% reported very good/excellent health status and 7.5% reported fair/poor health status prior to the COVID-19 pandemic (Table 3). At time of study enrollment, a higher percentage of participants without a history of infection reported at least a complete first vaccination series (97% compared to 56%). It is worth noting that enrollment for participants without a history of infection opened up in March 2022 when vaccinations were more widely available, likely accounting for this difference.

**Table 2** Baseline demographic characteristics of United States participants in the Johns Hopkins COVID Long Study

	Study Sample with SARS-CoV-2 Infection: Baseline Data <sup>1,2,3</sup> (n = 16,764)	Study Sample without SARS-CoV-2 Infection: Baseline Data <sup>1,4</sup> (n = 799)
Gender		
Cisgender man	2,514 (15%)	104 (13%)
Cisgender woman	14,010 (84%)	674 (85%)
Transgender man	24 (0.1%)	2 (0.3%)

**Table 2** Baseline demographic characteristics of United States participants in the Johns Hopkins COVID Long Study

	Study Sample with SARS-CoV-2 Infection: Baseline Data <sup>1,2,3</sup> (n = 16,764)	Study Sample without SARS-CoV-2 Infection: Baseline Data <sup>1,4</sup> (n = 799)
Transgender woman	14 (0.1%)	1 (0.1%)
Different identity	181 (1.1%)	16 (2.0%)
Missing	21	2
<b>Race</b>		
White	14,651 (88%)	651 (82%)
Black	489 (3.0%)	15 (1.9%)
Other	890 (5.4%)	100 (13%)
Mixed race	537 (3.2%)	24 (3.0%)
Missing	197	9
Hispanic, Latino or Spanish origin	1,323 (8.0%)	47 (5.9%)
Missing	122	5
Median age, IQR	43 (34,55)	42 (32,57)
Missing	45	3
<b>Educational attainment</b>		
High school, GED, or less	974 (5.8%)	30 (3.8%)
Some college, Associates/technical degree	4,150 (25%)	98 (12%)
Bachelor's degree	5,135 (31%)	241 (30%)
Post-graduate degree	6,461 (39%)	430 (54%)
Missing	44	0
<b>Annual household income</b>		
<\$25,000	1,588 (11%)	100 (14%)
\$25,000 - \$34,999	957 (6.7%)	42 (5.8%)
\$35,000 - \$49,999	1,486 (10%)	60 (8.3%)
\$50,000 - \$74,999	2,697 (19%)	118 (16%)
\$75,000 or greater	7,635 (53%)	405 (56%)
Missing	2,401	74
<b>Region</b>		
Northeast	3,159 (19%)	180 (23%)
Midwest	3,462 (21%)	141 (18%)
South	6,581 (39%)	281 (35%)
West	3,538 (21%)	197 (25%)
Missing	24	0

<sup>1</sup>Missing data were due to invalid data, "don't know" responses, "refuse to answer" responses, and missing responses. Percentages do not add up to 100% due to missing data. The number of missing data varies due to participants dropping out of the survey at different sections.

<sup>2</sup>Baseline data in participants with a history of SARS-CoV-2 infection is as of October 20, 2022.

<sup>3</sup>Limited to participants with a defined long COVID status. Long COVID status was determined using the [WHO definition](#). 320 participants without a defined long COVID status were excluded: 283 provided an initial SARS-CoV-2 infection date before the first confirmed positive test in the United States (January 20, 2020), 28 provided an invalid SARS-CoV-2 infection date, nine did not provide a SARS-CoV-2 infection date nor report experiencing symptoms of COVID-19.

<sup>4</sup>Baseline data in participants without a history of SARS-CoV-2 infection is as of February 14, 2023.

**Table 3** Baseline clinical characteristics of United States participants in the Johns Hopkins COVID Long Study

	Study Sample with SARS-CoV-2 Infection: Baseline Data <sup>1,2</sup> (n = 16,764)	Study Sample without SARS-CoV-2 Infection: Baseline Data <sup>1,3</sup> (n = 799)
Body mass index (kg/m <sup>2</sup> )		
Underweight (<18.5)	285 (1.8%)	13 (1.6%)
Normal weight (18.5 – 24.9)	5,517 (34%)	342 (43%)
Overweight (25 – 29.9)	4,643 (29%)	216 (27%)
Obese (30 and above)	5,827 (36%)	225 (28%)
Missing	492	3
Comorbid conditions		
Diabetes	716 (4.4%)	32 (4.0%)
Cardiovascular disease/congestive heart failure	379 (2.3%)	24 (3.0%)
Hypertension	2,526 (15%)	105 (13%)
Chronic kidney disease	138 (0.8%)	6 (0.8%)
Cancer	392 (2.4%)	17 (2.1%)
Asthma/reactive airway disease/chronic lung disease	2,684 (16%)	99 (12%)
Overweight/obese	4,853 (30%)	187 (23%)
Autoimmune disorder	1,568 (9.6%)	65 (8.1%)
Stroke	116 (0.7%)	9 (1.1%)
Depression/anxiety/other mental health condition	5,730 (35%)	286 (36%)
Missing	388	0
Self-rated health status prior to COVID-19 <sup>4</sup>		
Excellent	6,297 (38%)	283 (35%)
Very good	6,192 (37%)	321 (40%)
Good	2,900 (17%)	135 (17%)
Fair	1,242 (7.4%)	53 (6.6%)
Poor	126 (0.8%)	7 (0.9%)
Missing	7	0
Vaccination status at time of enrollment		
None = 0	6,414 (39%)	22 (2.8%)
Partial vaccination	805 (4.9%)	4 (0.5%)
Complete first series	4,006 (24%)	93 (12%)
≥1 Booster	5,208 (32%)	679 (85%)
Missing	331	1
Timing of initial SARS-CoV-2 infection		
January - June 2020	3,804 (23%)	N/A
July - December 2020	5,484 (33%)	N/A
January - June 2021	2,216 (13%)	N/A
July - December 2021	2,629 (16%)	N/A
≥January 2022	2,631 (16%)	N/A
Missing	0	N/A
Time between initial infection and survey completion in days (median (IQR))		
Missing	173 (70,382)	N/A
Missing	0	N/A
Symptom status at initial COVID-19 illness		
Symptomatic	16,588 (99%)	N/A
Asymptomatic	175 (1.0%)	N/A
Missing	1	N/A

**Table 3** Baseline clinical characteristics of United States participants in the Johns Hopkins COVID Long Study

	Study Sample with SARS-CoV-2 Infection: Baseline Data <sup>1,2</sup> (n = 16,764)	Study Sample without SARS-CoV-2 Infection: Baseline Data <sup>1,3</sup> (n = 799)
Presenting symptoms at initial COVID-19 illness		
Cardiopulmonary	15,140 (90%)	N/A
Neuropsychiatric	14,178 (85%)	N/A
Systemic	14,949 (89%)	N/A
Gastrointestinal	9,175 (55%)	N/A
Missing	0	N/A
Hospitalization status at initial COVID-19 illness		
Not hospitalized	14,839 (90%)	N/A
Hospitalized	1,627 (9.9%)	N/A
Missing	298	N/A
Long COVID status at survey completion <sup>5</sup>		
Has long COVID	10,518 (63%)	N/A
Does not have long COVID	1,246 (7.4%)	N/A
Cannot be determined <sup>6</sup>	5,000 (30%)	N/A

<sup>1</sup>Missing data were due to invalid data, “don’t know” responses, “refuse to answer” responses, and missing responses. Percentages do not add up to 100% due to missing data. The number of missing data varies due to participants dropping out of the survey at different sections.

<sup>2</sup>Baseline data in participants with a history of SARS-CoV-2 infection is as of October 20, 2022.

<sup>3</sup>Baseline data in participants without a history of SARS-CoV-2 infection is as of February 14, 2023.

<sup>4</sup>Participants with a history of SARS-CoV-2 infection were asked for self-rated health status prior to their COVID-19 illness. Participants without a history of SARS-CoV-2 infection were asked for self-rated health status prior to the COVID-19 pandemic.

<sup>5</sup>Limited to participants with a defined long COVID status. Long COVID status was determined using the [WHO definition](#). 320 participants without a defined long COVID status were excluded: 283 provided an initial SARS-CoV-2 infection date before the first confirmed positive test in the United States (January 20, 2020), 28 provided an invalid SARS-CoV-2 infection date, nine did not provide a SARS-CoV-2 infection date nor report experiencing symptoms of COVID-19.

<sup>6</sup>Long COVID status could not be determined because fewer than 12 weeks existed between initial SARS-CoV-2 infection and survey completion.

## STRENGTHS AND LIMITATIONS

The JHCLS is a large, online, prospective cohort study of adults with representation in 53 U.S. states and territories. The baseline survey collects comprehensive clinical and behavioral data, including data related to COVID-19 diagnosis and treatment, health history, pre-existing health conditions, and physical, mental, and cognitive limitations, and utilizes several reliable, validated scales to assess outcomes and exploratory variables. Participants are given the option to complete a one-time, anonymous online survey or to consent to longitudinal follow-up at predefined time intervals (every 3-6 months). In addition, overall participant burden is minimal.

A major strength of the JHCLS is that a positive SARS-CoV-2 test is not required to be eligible to participate. We recognize that testing is often limited or inaccessible, and thus require either a self-reported positive test or symptoms of COVID-19. In addition, our survey collects

1  
2  
3 data on a wide range of organ systems using several different validated measures. Despite  
4 early studies focusing primarily on the respiratory symptoms associated with initial COVID-19  
5 illness (e.g., shortness of breath), we appreciate that the SARS-CoV-2 virus may have notable  
6 effects on other organ systems following the acute period of infection as well.  
7  
8

9 Another strength of the JHCLS is the inclusion of participants without a history of SARS-  
10 CoV-2 infection which provides a natural control group, while also allowing for the determination  
11 of the incidence of long COVID among those who report a SARS-CoV-2 infection during follow-  
12 up. Importantly, both samples are comparable in terms of sociodemographic variables and pre-  
13 existing health conditions. We also recognize that many of the heterogeneous symptoms  
14 reported as long COVID may reflect all of us collectively living through a pandemic (i.e., anxiety,  
15 depression). Thus, it is important that we compare those with and without infection to evaluate  
16 some of these outcomes during the same time frame (versus retrospective or historical  
17 controls).  
18  
19

20 In addition, there are few longitudinal studies focused on post-acute outcomes of COVID-19.  
21 Longitudinal studies provide an opportunity to evaluate change over time in exposures and  
22 outcomes. The longitudinal collection of data on new/continuing COVID-19 symptoms at each  
23 time point during follow-up will allow for evaluation of resolution and persistence of symptoms  
24 over time, as well as the impact of re-infection, vaccination, and other health changes. To date,  
25 just under 7,000 participants have consented to participate in longitudinal follow-up and have  
26 completed their first follow-up survey.  
27  
28

29 The JHCLS also has a few limitations. The reliance on self-reported clinical data may result  
30 in recall and measurement bias. A second limitation is the possibility of selection bias due to the  
31 fact that the survey must be completed using a smart device or computer with internet access.  
32 This may preclude participants from lower socioeconomic statuses from participating.  
33 Additionally, many individuals enroll many months after their acute infection when they already  
34 have long COVID. A potential selection bias would include increased likelihood of participation  
35 among those with more severe long COVID. However, it is important to note that the JHCLS  
36 has a subset of individuals ( $n = 2,020$ ) who enrolled during their acute infection (within four  
37 weeks of infection). Another limitation is the possibility of recall bias, especially among  
38 participants with a history of COVID-19 illness experiencing mental fatigue and/or other  
39 cognitive limitations at the time of survey completion. Finally, there is a risk that findings from  
40 the JHCLS are not generalizable as the majority of participants self-reported white race and are  
41 from a higher socioeconomic status. However, whether a study is representative or not depends  
42 not on demographics but on potential effect measure modifiers that may or may not include  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 demographics.(27) Additionally, results that may not necessarily be generalizable in the effect  
4 estimate may still be generalizable in the direction of effect (e.g., protective or increased risk) of  
5 an exposure on outcome.(27)  
6  
7

### 8 9 **Future plans**

10 Moving forward, the JHCLS will continue to enroll additional participants with and without a  
11 history of SARS-CoV-2 infection and collect data from the baseline and longitudinal surveys.  
12 The study team is in the initial stages of analyzing the longitudinal data collected thus far,  
13 focusing on the progression and resolution of long COVID symptoms over time. In the future,  
14 the study team may apply for funding to answer additional research questions and to continue  
15 following the longitudinal participants for a longer period of time.  
16  
17  
18  
19

20 The JHCLS has the potential to impact both our overall understanding of long COVID and  
21 our ability to identify subgroups of individuals for targeted interventions. We can also capture  
22 real-time changes by SARS-CoV-2 variants (based on calendar time), location (using geospatial  
23 data), birth/age cohorts, and/or vaccine data.  
24  
25  
26  
27

### 28 29 **COLLABORATION**

30 The JHCLS invites researchers to contact the corresponding author for collaboration  
31 opportunities.  
32  
33

### 34 35 **Acknowledgements**

36 We would like to express our deepest appreciation to our participants for their dedication,  
37 unwavering commitment, and vulnerability in sharing their stories with us. We would also like to  
38 thank the REDCap team at the Johns Hopkins Bloomberg School of Public Health for their  
39 continued assistance and guidance. This endeavor would not have been possible without their  
40 help. Lastly, we'd like to acknowledge and thank our student researchers.  
41  
42  
43  
44

### 45 46 **Author contributions**

47 B. Lau, P. Duggal, and S.H. Mehta conceived the original study concept and design and act  
48 as Co-Principal Investigators. They take responsibility for the integrity of the data. B. Lau, P.  
49 Duggal, S.H. Mehta, and E. Wentz were responsible for the acquisition of the data. E. Wentz  
50 prepared the first draft of this manuscript, under the supervision of B. Lau, P. Duggal, and S.H.  
51 Mehta. E. Wentz, Z. Ni, K. Yenokyan, C. Coggiano, J. Pahwa, T. Kammerling, P. Xiao, P.  
52 Duggal, B. Lau, and S.H. Mehta were involved in reviewing the manuscript and contributing to  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 critical revisions. Administrative and technical support was provided by E. Wentz, C. Coggiano,  
4 Z. Ni, J. Pahwa, T. Kammerling, and P. Xiao.  
5  
6

### 7 **Funding**

8  
9 The study is supported by the Johns Hopkins University COVID-19 Research Response  
10 Program and in part by the Johns Hopkins University Center for AIDS Research (P30AI094189),  
11 which is supported by the following NIH Co-Funding and Participating Institutes and Centers:  
12 NIAID, NCI, NICHD, NHLBI, NIDA, NIA, NIGMS, NIDDK, NIMHD. The content is solely the  
13 responsibility of the authors and does not necessarily represent the official views of the NIH.  
14  
15  
16  
17

### 18 **Competing interests**

19 S.H. Mehta receives materials support from Abbott Laboratories (not related to this study).  
20  
21

### 22 **Patient consent for publication**

23 Not applicable.  
24  
25

### 26 **Ethics approval**

27  
28 The study protocol was approved and exempted by the Institutional Review Board at the  
29 Johns Hopkins Bloomberg School of Public Health (IRB00014874) on January 8, 2021.  
30  
31

### 32 **Data sharing statement**


33 Not applicable.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Bourmistrova NW, Solomon T, Braude P, Strawbridge R, Carter B. Long-term effects of COVID-19 on mental health: A systematic review. *J Affect Disord*. 2022 Feb;299:118–25.
2. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. *Nat Med*. 2021 Apr;27(4):601–15.
3. Raman B, Bluemke DA, Lüscher TF, Neubauer S. Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. *Eur Heart J*. 2022 Mar 14;43(11):1157–72.
4. Montani D, Savale L, Noel N, Meyrignac O, Colle R, Gasnier M, et al. Post-acute COVID-19 syndrome. *Eur Respir Rev*. 2022 Mar 31;31(163):210185.
5. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. *Lancet Infect Dis*. 2022 Apr;22(4):e102–7.
6. Perlis RH, Santillana M, Ognyanova K, Safarpour A, Lunz Trujillo K, Simonson MD, et al. Prevalence and Correlates of Long COVID Symptoms Among US Adults. *JAMA Netw Open*. 2022 Oct 27;5(10):e2238804.
7. Van Kessel SAM, Olde Hartman TC, Lucassen PLBJ, Van Jaarsveld CHM. Post-acute and long-COVID-19 symptoms in patients with mild diseases: a systematic review. *Fam Pract*. 2022 Jan 19;39(1):159–67.
8. Domingo FR, Waddell LA, Cheung AM, Cooper CL, Belcourt VJ, Zuckermann AME, et al. Prevalence of long-term effects in individuals diagnosed with COVID-19: an updated living systematic review [Internet]. *Epidemiology*; 2021 Jun [cited 2023 Jun 28]. Available from: <http://medrxiv.org/lookup/doi/10.1101/2021.06.03.21258317>
9. Castanares-Zapatero D, Chalon P, Kohn L, Dauvrin M, Detollenaere J, Maertens De Noordhout C, et al. Pathophysiology and mechanism of long COVID: a comprehensive review. *Ann Med*. 2022 Dec 31;54(1):1473–87.
10. Rodriguez-Sanchez I, Rodriguez-Mañas L, Laosa O. Long COVID-19: The Need for an Interdisciplinary Approach. *Clin Geriatr Med*. 2022 Aug;38(3):533–44.
11. Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. *Nat Med*. 2022 May;28(5):911–23.
12. Ramakrishnan RK, Kashour T, Hamid Q, Halwani R, Tleyjeh IM. Unraveling the Mystery Surrounding Post-Acute Sequelae of COVID-19. *Front Immunol*. 2021 Jun 30;12:686029.
13. Pavli A, Theodoridou M, Maltezou HC. Post-COVID Syndrome: Incidence, Clinical Spectrum, and Challenges for Primary Healthcare Professionals. *Arch Med Res*. 2021 Aug;52(6):575–81.
14. Karuna S, Gallardo-Cartagena JA, Theodore D, Hunidzarira P, Montenegro-Idrogo J, Hu J, et al. Post-COVID symptom profiles and duration in a global convalescent COVID-19 observational cohort: Correlations with demographics, medical history, acute COVID-19 severity and global region. *J Glob Health*. 2023 Jun 23;13:06020.



15. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform.* 2009 Apr;42(2):377–81.
16. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: Building an international community of software platform partners. *J Biomed Inform.* 2019 Jul;95:103208.
17. Ferrucci L. The Baltimore Longitudinal Study of Aging (BLSA): a 50-year-long journey and plans for the future. *J Gerontol A Biol Sci Med Sci.* 2008 Dec;63(12):1416–9.
18. Stone JL, Norris AH. Activities and Attitudes of Participants in the Baltimore Longitudinal Study. *J Gerontol.* 1966 Oct 1;21(4):575–80.
19. Gaston Godin. The Godin--Shephard Leisure--Time Physical Activity Questionnaire. *Health Fit J Can.* 2011;4(1):18–22.
20. Godin G, Shephard RJ. A simple method to assess exercise behavior in the community. *Can J Appl Sport Sci J Can Sci Appl Au Sport.* 1985 Sep;10(3):141–6.
21. Amireault S, Godin G. The Godin-Shephard Leisure-Time Physical Activity Questionnaire: Validity Evidence Supporting its Use for Classifying Healthy Adults into Active and Insufficiently Active Categories. *Percept Mot Skills.* 2015 Apr;120(2):604–22.
22. Vlahov D, Anthony JC, Munoz A, Margolick J, Nelson KE, Celentano DD, et al. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. *NIDA Res Monogr.* 1991;109:75–100.
23. Rassu AL, Evangelista E, Barateau L, Chenini S, Lopez R, Jaussent I, et al. Idiopathic Hypersomnia Severity Scale to better quantify symptoms severity and their consequences in idiopathic hypersomnia. *J Clin Sleep Med.* 2022 Feb;18(2):617–29.
24. Dauvilliers Y, Evangelista E, Barateau L, Lopez R, Chenini S, Delbos C, et al. Measurement of symptoms in idiopathic hypersomnia: The Idiopathic Hypersomnia Severity Scale. *Neurology.* 2019 Apr 9;92(15):e1754–62.
25. Bentall RP, Wood GC, Marrinan T, Deans C, Edwards RHT. A brief mental fatigue questionnaire. *Br J Clin Psychol.* 1993 Sep;32(3):375–7.
26. Spitzer RL, Kroenke K, Williams JBW, Löwe B. A Brief Measure for Assessing Generalized Anxiety Disorder: The GAD-7. *Arch Intern Med.* 2006 May 22;166(10):1092.
27. Jacqueline E Rudolph, Yongqi Zhong, Priya Duggal, Shruti H Mehta, Bryan Lau. Defining representativeness of study samples in medical and population health research. *BMJ Med.* 2023 May 1;2(1):e000399.



**Figure 1** Flow diagram showing United States recruitment into the Johns Hopkins COVID Long Study

480x587mm (130 x 130 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

**Table 1** Survey measures

Domain	Questionnaire	Variable Description	Validation	Scoring
SARS-CoV-2 Testing and COVID-19 Symptoms	Self-designed	General health before COVID-19 illness (population with history of SARS-CoV-2 infection) or COVID-19 pandemic (population without history of SARS-CoV-2 infection), SARS-CoV-2 testing (number of times, result, exposure, test type, month/year of first positive test), month/year of initial symptom onset, symptoms experienced during initial illness, new/continuing symptoms experienced after initial illness, impact of each symptom on daily activities, self-reported recovery compared to before COVID-19 illness (population with history of SARS-CoV-2 infection) or COVID-19 pandemic (population without history of SARS-CoV-2 infection)	N/A	Categorical responses
Vaccines and SARS-CoV-2 Re-infection	Self-designed	Flu vaccine uptake, COVID-19 vaccine uptake (number of doses, series type, month/year per dose), SARS-CoV-2 antibody testing (month/year of testing, result), COVID-19 treatment trials, COVID-19 re-infection (number of times, exposure, test type, month/year of each positive test, month/year of each symptom onset), comparison of first re-infection to initial infection	N/A	Categorical responses
COVID-19 Treatments and Hospitalizations	Self-designed	Treatments for COVID-19, treatments for new/continuing COVID-19 symptoms, hospitalizations (number of days, severity), health care utilization (pre-COVID-19 illness and current), health seeking behavior to treat symptoms	N/A	Categorical responses
Comorbidities	Self-designed	Self-reported current health status, pre-existing health conditions, cancer diagnosis (type, diagnosis timeframe, treatments), height, weight, current stress level, stress level before the COVID-19 pandemic	N/A	Categorical responses

**Table 1** Continued

Domain	Questionnaire	Variable Description	Validation	Scoring
Limitations and Exercise	Baltimore Longitudinal Study of Aging(17,18)	Overall physical limitations before COVID-19 illness (population with history of SARS-CoV-2 infection) or COVID-19 pandemic (population without history of SARS-CoV-2 infection), difficulty walking a quarter of a mile/one mile, difficulty walking up 10 steps/20 steps, difficulty with performing light housework/heavy housework, difficulty level (if difficulty reported), level of ease (if no difficulty reported), indicator for incident/prevalent disability	N/A	<p><u>Mobility disability</u>: Any level of difficulty walking a quarter of a mile</p> <p><u>Instrumental activities of daily living disability</u>: Any level of difficulty with light housework</p>
	Godin-Shephard Leisure-Time Physical Activity Questionnaire(19–21)	Number of times in a typical week doing strenuous, moderate, and mild intensity exercise for more than 15 minutes before and after COVID-19 illness (population with history of SARS-CoV-2 infection) or COVID-19 pandemic (population without history of SARS-CoV-2 infection)	<p>Validated in population of healthy adults</p> <p>Test-retest reliability: 0.94 for strenuous exercise, 0.46 for moderate exercise, and 0.48 for light exercise</p>	<p>1) Multiply number of times per week per category by Metabolic Equivalent of Task factor (3 for light, 5 for moderate, 9 for strenuous)</p> <p>2) Sum scores for total leisure time activity score</p> <ul style="list-style-type: none"> <li>• <math>\geq 24</math>: active lifestyle</li> <li>• 14-23: moderately active lifestyle</li> <li>• <math>&lt; 14</math>: sedentary lifestyle</li> </ul>
Sleep Quality	AIDS Linked to the IntraVenous Experience (ALIVE) Study(22)	Total hours slept in typical 24-hour period, overall sleep quality during last four weeks, insomnia (difficulty falling/staying asleep)	N/A	Categorical responses
	Idiopathic Hypersomnia Severity Scale(23,24)	Four indicators of hypersomnia (assessment of sleep adequacy, difficulty waking up, length of time to feel fully functioning upon waking, struggling to stay awake during the day)	<p>Validated in patients experiencing idiopathic hypersomnia</p> <p>High internal consistency (Cronbach <math>\alpha=.89</math>) and good content validity</p>	<p>1) Each item is assigned a score (0-3 or 0-4)</p> <p>2) Sum scores for a total of 0-14</p> <p>Higher scores represent more severe/frequent symptoms of idiopathic hypersomnia</p>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

<b>Domain</b>	<b>Questionnaire</b>	<b>Variable Description</b>	<b>Validation</b>	<b>Scoring</b>
Cognition	Wood Mental Fatigue Inventory (WMFI)(25)	Nine indicators of mental fatigue over last two weeks (confusion, mixed thoughts, poor concentration, difficulty with decision making, memory problems, issues taking things in, slow thoughts, muzzy head, issues finding words)	Validated in patients with ME/CFS  High internal consistency (Cronbach $\alpha$ =.93) and good test-retest reliability (Pearson's $r$ = 0.887)	1) Each item is assigned a score from 0-4  2) Sum scores for total of 0-36  Higher scores indicate greater levels of mental fatigue
Anxiety	Generalized Anxiety Disorder-7 (GAD-7)(26)	Seven indicators of anxiety over last two weeks (feeling anxious, not able to control worrying, worrying about different things, trouble relaxing, restlessness, irritability, feeling afraid)	Validated in general population  High internal consistency (Cronbach $\alpha$ =.92)  Good criterion, construct, factorial, and procedural validity	1) Each item is assigned a score from 0-3  2) Sum scores for total of 0-21  <ul style="list-style-type: none"> <li>• 0-4: no anxiety disorder</li> <li>• 5-9: mild anxiety disorder</li> <li>• 10-14: moderate anxiety disorder</li> <li>• <math>\geq</math>15: severe anxiety disorder</li> </ul>
Demographics	Self-designed	Work activities prior to the COVID-19 pandemic, primary occupation, household income in 2019, number of dependents	N/A	Categorical responses

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

For peer review only

**Table 2.** Baseline demographic characteristics of United States participants in the Johns Hopkins COVID Long Study

	Study Sample with SARS-CoV-2 Infection: Baseline Data <sup>1,2,3</sup> (n = 16,764)	Study Sample without SARS-CoV-2 Infection: Baseline Data <sup>1,4</sup> (n = 799)
<b>Gender</b>		
Cisgender man	2,514 (15%)	104 (13%)
Cisgender woman	14,010 (84%)	674 (85%)
Transgender man	24 (0.1%)	2 (0.3%)
Transgender woman	14 (0.1%)	1 (0.1%)
Different identity	181 (1.1%)	16 (2.0%)
Missing	21	2
<b>Race</b>		
White	14,651 (88%)	651 (82%)
Black	489 (3.0%)	15 (1.9%)
Other	890 (5.4%)	100 (13%)
Mixed race	537 (3.2%)	24 (3.0%)
Missing	197	9
Hispanic, Latino or Spanish origin	1,323 (8.0%)	47 (5.9%)
Missing	122	5
Median age, IQR	43 (34,55)	42 (32,57)
Missing	45	3
<b>Educational attainment</b>		
High school, GED, or less	974 (5.8%)	30 (3.8%)
Some college, Associates/technical degree	4,150 (25%)	98 (12%)
Bachelor's degree	5,135 (31%)	241 (30%)
Post-graduate degree	6,461 (39%)	430 (54%)
Missing	44	0
<b>Annual household income</b>		
<\$25,000	1,588 (11%)	100 (14%)
\$25,000 - \$34,999	957 (6.7%)	42 (5.8%)
\$35,000 - \$49,999	1,486 (10%)	60 (8.3%)
\$50,000 - \$74,999	2,697 (19%)	118 (16%)
\$75,000 or greater	7,635 (53%)	405 (56%)
Missing	2,401	74
<b>Region</b>		
Northeast	3,159 (19%)	180 (23%)
Midwest	3,462 (21%)	141 (18%)
South	6,581 (39%)	281 (35%)
West	3,538 (21%)	197 (25%)
Missing	24	0

<sup>1</sup>Missing data were due to invalid data, "don't know" responses, "refuse to answer" responses, and missing responses.

Percentages do not add up to 100% due to missing data. The number of missing data varies due to participants dropping out of the survey at different sections.

<sup>2</sup>Baseline data in participants with a history of SARS-CoV-2 infection is as of October 20, 2022.

<sup>3</sup>Limited to participants with a defined long COVID status. Long COVID status was determined using the [WHO definition](#).

320 participants without a defined long COVID status were excluded: 283 provided an initial SARS-CoV-2 infection date before the first confirmed positive test in the United States (January 20, 2020), 28 provided an invalid SARS-CoV-2 infection date, nine did not provide a SARS-CoV-2 infection date nor report experiencing symptoms of COVID-19.

<sup>4</sup>Baseline data in participants without a history of SARS-CoV-2 infection is as of February 14, 2023.

For peer review only



**Table 3.** Baseline clinical characteristics of United States participants in the Johns Hopkins COVID Long Study

	Study Sample with SARS-CoV-2 Infection: Baseline Data <sup>1,2</sup> (n = 16,764)	Study Sample without SARS-CoV-2 Infection: Baseline Data <sup>1,3</sup> (n = 799)
Body mass index (kg/m <sup>2</sup> )		
Underweight (<18.5)	285 (1.8%)	13 (1.6%)
Normal weight (18.5 – 24.9)	5,517 (34%)	342 (43%)
Overweight (25 – 29.9)	4,643 (29%)	216 (27%)
Obese (30 and above)	5,827 (36%)	225 (28%)
Missing	492	3
Comorbid conditions		
Diabetes	716 (4.4%)	32 (4.0%)
Cardiovascular disease/congestive heart failure	379 (2.3%)	24 (3.0%)
Hypertension	2,526 (15%)	105 (13%)
Chronic kidney disease	138 (0.8%)	6 (0.8%)
Cancer	392 (2.4%)	17 (2.1%)
Asthma/reactive airway disease/chronic lung disease	2,684 (16%)	99 (12%)
Overweight/obese	4,853 (30%)	187 (23%)
Autoimmune disorder	1,568 (9.6%)	65 (8.1%)
Stroke	116 (0.7%)	9 (1.1%)
Depression/anxiety/other mental health condition	5,730 (35%)	286 (36%)
Missing	388	0
Self-rated health status prior to COVID-19 <sup>4</sup>		
Excellent	6,297 (38%)	283 (35%)
Very good	6,192 (37%)	321 (40%)
Good	2,900 (17%)	135 (17%)
Fair	1,242 (7.4%)	53 (6.6%)
Poor	126 (0.8%)	7 (0.9%)
Missing	7	0
Vaccination status at time of enrollment		
None = 0	6,414 (39%)	22 (2.8%)
Partial vaccination	805 (4.9%)	4 (0.5%)
Complete first series	4,006 (24%)	93 (12%)
≥1 Booster	5,208 (32%)	679 (85%)
Missing	331	1
Timing of initial SARS-CoV-2 infection		
January - June 2020	3,804 (23%)	N/A
July - December 2020	5,484 (33%)	N/A
January - June 2021	2,216 (13%)	N/A
July - December 2021	2,629 (16%)	N/A
≥January 2022	2,631 (16%)	N/A
Missing	0	N/A

**Table 3.** Baseline clinical characteristics of United States participants in the Johns Hopkins COVID Long Study

	Study Sample with SARS-CoV-2 Infection: Baseline Data <sup>1,2</sup> (n = 16,764)	Study Sample without SARS-CoV-2 Infection: Baseline Data <sup>1,3</sup> (n = 799)
Time between initial infection and survey completion in days (median (IQR))	173 (70,382)	N/A
Missing	0	N/A
Symptom status at initial COVID-19 illness		
Symptomatic	16,588 (99%)	N/A
Asymptomatic	175 (1.0%)	N/A
Missing	1	N/A
Presenting symptoms at initial COVID-19 illness		
Cardiopulmonary	15,140 (90%)	N/A
Neuropsychiatric	14,178 (85%)	N/A
Systemic	14,949 (89%)	N/A
Gastrointestinal	9,175 (55%)	N/A
Missing	0	N/A
Hospitalization status at initial COVID-19 illness		
Not hospitalized	14,839 (90%)	N/A
Hospitalized	1,627 (9.9%)	N/A
Missing	298	N/A
Long COVID status at survey completion <sup>5</sup>		
Has long COVID	10,518 (63%)	N/A
Does not have long COVID	1,246 (7.4%)	N/A
Cannot be determined <sup>6</sup>	5,000 (30%)	N/A

<sup>1</sup>Missing data were due to invalid data, “don’t know” responses, “refuse to answer” responses, and missing responses. Percentages do not add up to 100% due to missing data. The number of missing data varies due to participants dropping out of the survey at different sections.

<sup>2</sup>Baseline data in participants with a history of SARS-CoV-2 infection is as of October 20, 2022.

<sup>3</sup>Baseline data in participants without a history of SARS-CoV-2 infection is as of February 14, 2023.

<sup>4</sup>Participants with a history of SARS-CoV-2 infection were asked for self-rated health status prior to their COVID-19 illness. Participants without a history of SARS-CoV-2 infection were asked for self-rated health status prior to the COVID-19 pandemic.

<sup>5</sup>Limited to participants with a defined long COVID status. Long COVID status was determined using the [WHO definition](#).

320 participants without a defined long COVID status were excluded: 283 provided an initial SARS-CoV-2 infection date before the first confirmed positive test in the United States (January 20, 2020), 28 provided an invalid SARS-CoV-2 infection date, nine did not provide a SARS-CoV-2 infection date nor report experiencing symptoms of COVID-19.

<sup>6</sup>Long COVID status could not be determined because fewer than 12 weeks existed between initial SARS-CoV-2 infection and survey completion.

# BMJ Open

## Cohort profile: the Johns Hopkins COVID Long Study (JHCLS), a United States Nationwide Prospective Cohort Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-077742.R1
Article Type:	Cohort profile
Date Submitted by the Author:	21-Nov-2023
Complete List of Authors:	Wentz, Eryka; Johns Hopkins University Bloomberg School of Public Health, Epidemiology Ni, Zhanmo; Johns Hopkins School of Medicine, Oncology Yenokyan, Karine; Johns Hopkins University Bloomberg School of Public Health, Epidemiology Vergara, Candelaria; Johns Hopkins University Bloomberg School of Public Health, Epidemiology Pahwa, Jessica; Johns Hopkins University Bloomberg School of Public Health, Epidemiology Kammerling, Thea; Johns Hopkins University Bloomberg School of Public Health, Epidemiology Xiao, Pu; Johns Hopkins University Whiting School of Engineering, Data Science Duggal, Priya; Johns Hopkins University Bloomberg School of Public Health, Epidemiology Lau, Bryan; Johns Hopkins University Bloomberg School of Public Health, General Epidemiology and Methodology Mehta, Shruti; Johns Hopkins University Bloomberg School of Public Health, Epidemiology
<b>Primary Subject Heading</b>:	Epidemiology
Secondary Subject Heading:	Infectious diseases
Keywords:	COVID-19, INFECTIOUS DISEASES, Chronic Disease, EPIDEMIOLOGIC STUDIES

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

## Cohort profile: the Johns Hopkins COVID Long Study (JHCLS), a United States Nationwide Prospective Cohort Study

Eryka Wentz, MA, Zhanmo Ni, MHS, Karine Yenokyan, PhD, Candelaria Vergara, MD, Jessica Pahwa, MPH, Thea Kammerling, BA, Pu Xiao, BS, Priya Duggal, PhD, Bryan Lau, PhD, Shruti H. Mehta, PhD

**Corresponding author:** Eryka Wentz, 615 N. Wolfe Street, Baltimore, MD 21205, [ewentz1@jhu.edu](mailto:ewentz1@jhu.edu), (410) 834-1603 (phone), (410) 614-0902 (fax)

**Eryka Wentz**, Johns Hopkins Bloomberg School of Public Health, Baltimore, United States of America

**Zhanmo Ni**, Johns Hopkins School of Medicine, Baltimore, United States of America

**Karine Yenokyan**, Johns Hopkins Bloomberg School of Public Health, Baltimore, United States of America

**Candelaria Vergara**, Johns Hopkins Bloomberg School of Public Health, Baltimore, United States of America

**Jessica Pahwa**, Johns Hopkins Bloomberg School of Public Health, Baltimore, United States of America

**Thea Kammerling**, Johns Hopkins Bloomberg School of Public Health, Baltimore, United States of America

**Pu Xiao**, Johns Hopkins Whiting School of Engineering, Baltimore, United States of America

**Priya Duggal**, Johns Hopkins Bloomberg School of Public Health, Baltimore, United States of America

**Bryan Lau**, Johns Hopkins Bloomberg School of Public Health, Baltimore, United States of America

**Shruti H. Mehta**, Johns Hopkins Bloomberg School of Public Health, Baltimore, United States of America

**Keywords:** COVID-19, SARS-CoV-2, Infectious Diseases, Chronic Disease, Epidemiologic Studies

**Word count:** 4,310

### ABSTRACT

**Purpose** COVID-19 disease continues to affect millions of individuals worldwide, both in the short and long term. The post-acute complications of SARS-CoV-2 infection, referred to as long COVID, result in diverse symptoms affecting multiple organ systems. Little is known regarding how the symptoms associated with long COVID progress and resolve over time. The Johns Hopkins COVID Long Study aims to prospectively examine the short- and long-term consequences of COVID-19 disease in individuals both with and without a history of SARS-CoV-2 infection using self-reported data collected in an online survey.

**Participants** Sixteen thousand, seven hundred sixty-four adults with a history of SARS-CoV-2 infection and 799 adults without a history of SARS-CoV-2 infection who completed an online baseline survey.

**Findings to date** This cohort profile describes the baseline characteristics of the Johns Hopkins COVID Long Study. Among 16,764 participants with a history of SARS-CoV-2 infection

1  
2  
3 and defined long COVID status, 75% reported a good or excellent health status prior to  
4 infection, 99% reported experiencing at least one COVID-19 symptom during the acute phase of  
5 infection, 9.9% reported a hospitalization, and 63% were defined as having long COVID using  
6 the WHO definition.  
7

8 **Future plans** Analysis of longitudinal data will be used to investigate the progression and  
9 resolution of long COVID symptoms over time.  
10

## 11 12 13 14 **ARTICLE SUMMARY**

### 15 16 **Strengths and limitations of this study**

- 17  
18 • The Johns Hopkins COVID Long Study (JHCLS) is a large, online, prospective cohort study of  
19 adults that collects comprehensive clinical and behavioral data on participants with and  
20 without a history of SARS-CoV-2 infection at baseline with an option to participate in  
21 longitudinal follow-up every 3-6 months.  
22
- 23 • Detailed clinical data are collected on COVID-19 diagnosis and treatment, health history, and  
24 pre-existing health conditions, in addition to validated measurements on physical, mental, and  
25 cognitive limitations.  
26
- 27 • The JHCLS is comprised of participants from 53 United States and territories and includes  
28 individuals aged 19-96 years.  
29
- 30 • Because SARS-CoV-2 tests are not always accessible, eligibility requirements include either  
31 a self-reported positive SARS-CoV-2 test or symptoms of COVID-19.  
32
- 33 • There may be selection and recall bias due to the increased likelihood of participation by  
34 individuals with long COVID and self-reported clinical data; however, the JHCLS is comprised  
35 of a subset of individuals who enrolled within four weeks of their initial SARS-CoV-2 infection  
36 and had not yet developed long COVID.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

Since its emergence in 2019, COVID-19 has greatly affected the health and well-being of millions of people worldwide.(1,2) Both acute and persistent post-infection complications have been reported by patients(3) and COVID-19 is now recognized as a multi-organ disease.(4) The World Health Organization (WHO) defines persistent post-infection complications, referred to as long COVID, as new or continuing symptoms three months after initial illness that last at least two months and cannot be explained otherwise.(5) Despite recent studies suggesting that long COVID may occur in 10-55% of individuals exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),(6–8) the exact incidence remains unknown. There is also uncertainty in the pathophysiology and symptomatology of long COVID.(9,10) With the elevated burden of COVID-19 worldwide, it is important to understand the full range of symptoms and long-term outcomes.(2) Moreover, the large number of individuals requiring continued medical care will pose an economic burden on our health care system.(10)

Similar to other infections, SARS-CoV-2 is associated with post-acute infection syndromes resulting in a variety of symptoms.(11) Some of the core symptoms associated with long COVID are common to other post-acute infection syndromes as well, including but not limited to fatigue, exertion intolerance, and neurocognitive impairment.(11) Despite our general knowledge of the occurrence of post-acute infection syndromes, it is largely understudied. Cohort studies composed of those who have had SARS-CoV-2 and those who have not (i.e., control population) are critical to understanding the gaps in our knowledge of long COVID and post-acute infections in general.

The presentation of those with long COVID is often marked with multiple diverse symptoms affecting multiple organs; each individual may have their own unique clinical presentation.(12) Though age is a major risk factor in COVID-19 related mortality, and despite a preponderance of long COVID among those aged 40 - 60 years, long COVID is reported across the age spectrum.(13) Similarly, long COVID is reported by persons of all genders, race/ethnicities, and those with and without pre-existing comorbidities.(13,14) Hence, it is essential that research both identifies and characterizes the main clinical and epidemiological features associated with long COVID, including potential targets for intervention.

For these reasons, the Johns Hopkins COVID Long Study (JHCLS) was established to prospectively examine the short- and long-term consequences of COVID-19 over a 3-year follow-up period. The overall objectives of the JHCLS are to (1) characterize the spectrum of long-term sequelae of SARS-CoV-2 infection; (2) identify individuals at risk for long-term sequelae; and (3) characterize the physical and mental health disability associated with long

1  
2  
3 COVID. To meet study objectives, the cohort includes participants with and without a history of  
4 SARS-CoV-2 infection. This cohort profile describes baseline demographic and clinical  
5 characteristics of United States (U.S.) participants enrolled in the JHCLS.  
6  
7  
8  
9

## 10 **COHORT DESCRIPTION**

### 11 **Study design and participants**

12  
13 The JHCLS launched for participants with a self-reported history of SARS-CoV-2 infection  
14 on February 2, 2021, and expanded to include participants without a history of SARS-CoV-2  
15 infection on March 2, 2022. All consenting participants are asked to complete a one-time, short  
16 online baseline survey with the option to remain anonymous. At the end of the baseline survey,  
17 participants are asked if they agree to be contacted for future COVID-19 studies, such as  
18 enrollment into longitudinal follow-up. If they respond yes, they are contacted by email or phone  
19 3-6 months later with information about participating in longitudinal follow-up. If they  
20 subsequently consent to participate in longitudinal follow-up, they are emailed a follow-up  
21 survey every 3-6 months.  
22  
23  
24  
25  
26  
27  
28

29 As of February 14, 2023, 20,319 participants with a self-reported history of SARS-CoV-2  
30 infection and 1,041 participants without a history of SARS-CoV-2 infection consented to  
31 participate in the JHCLS (Figure 1). Of the 20,319 participants with a history of infection, 15,478  
32 with a defined long COVID status (76%) completed the baseline survey and 11,924 (59%)  
33 consented to be contacted for future studies. Of these, 6,327 have enrolled in longitudinal  
34 follow-up and completed their first follow-up survey. Of the 1,041 participants without a history of  
35 infection, 799 (77%) completed the baseline survey and 501 (48%) consented to be contacted  
36 for future studies. Of these, 278 have enrolled in longitudinal follow-up and completed their first  
37 follow-up survey. At each round of follow-up, participants without a history of infection are asked  
38 if they have experienced COVID-19 symptoms or tested positive for SARS-CoV-2 since their  
39 last survey completion. If they respond yes, they are transferred to the survey for participants  
40 with a history of infection. As of February 14, 2023, 46 of the 278 participants (17%) who  
41 completed their first round of longitudinal follow-up have self-reported either a positive SARS-  
42 CoV-2 test or symptoms of COVID-19. The median survey completion time is 20 minutes for the  
43 baseline survey and 24 minutes for the first follow-up survey.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53

### 54 **Recruitment**



1  
2  
3 Participants are recruited into the JHCLS using several mechanisms: social media posts,  
4 Facebook ad campaigns, direct messaging (e.g., emails to health departments), word of mouth,  
5 and participation in a recruitment registry. For social media recruitment, researchers utilize  
6 study-owned and operated Instagram, Facebook, and Twitter accounts. In addition, the team  
7 partnered with the Audience Development Team at the Johns Hopkins Bloomberg School of  
8 Public Health (BSPH) Communications Department to develop targeted Facebook ad  
9 campaigns. The study ran three Facebook ad campaigns, each targeting a neighborhood in the  
10 U.S. with high SARS-CoV-2 case counts. Two campaigns ran in April 2021, the first targeting  
11 neighborhoods in Detroit, Michigan, and the second in Fayetteville and Hope Mills, North  
12 Carolina, and South Fulton and Alpharetta, Georgia. The final campaign ran in July 2021 and  
13 targeted neighborhoods in Houston and San Antonio, Texas, Miami and Jacksonville, Florida,  
14 and Los Angeles, California.

15  
16  
17  
18  
19  
20  
21  
22 The study team also partners with the Johns Hopkins Opportunities for Participant  
23 Engagement (HOPE) Registry. The HOPE Registry (<http://johnshopkinshope.org/>) is a  
24 recruitment registry designed to connect individuals with teams conducting COVID-19 research  
25 studies at Johns Hopkins University. The JHCLS was officially enrolled into the HOPE Registry  
26 in April 2021.

### 27 28 29 30 31 **Participant eligibility**

32  
33 The JHCLS was approved and determined to be exempt by the Institutional Review Board  
34 (IRB) at the BSPH on January 8, 2021.

35  
36 To be eligible to participate in the study, participants must be at least 18 years of age.  
37 Additionally, to be eligible to complete the survey for participants with a history of SARS-CoV-2  
38 infection, participants must self-report at least one positive SARS-CoV-2 test or symptoms of  
39 COVID-19. At the start of the baseline survey, eligible participants are provided with a short,  
40 informed consent script that details the purpose of the study and provides details on  
41 participation. In order to protect the confidentiality of participants, participants are assigned a  
42 unique study identifier number and data are collected anonymously.

### 43 44 45 46 47 48 **Study procedures**

49  
50 The JHCLS baseline survey is self-administered and collects data across nine domains:  
51 SARS-CoV-2 testing and COVID-19 symptoms, vaccines and SARS-CoV-2 re-infection,  
52 COVID-19 treatments and hospitalizations, pre-existing comorbidities, physical limitations and  
53 exercise, sleep quality, mental fatigue, anxiety, and demographics (Supplementary Table 1).  
54 Data from these same domains are collected during longitudinal follow-up as well. All data are  
55  
56  
57  
58  
59  
60

1  
2  
3 collected in REDCap, a HIPAA-compliant, secure web application designed to build and  
4 manage online surveys and databases.(15,16) Most survey questions were adapted from  
5 validated measures and assessments. However, certain questions were self-designed for the  
6 purpose of meeting study objectives. All self-designed questionnaires are available on the  
7 National Institute of Environmental Health Sciences Disaster Research Response (DR2)  
8 Resources Portal (<https://tools.niehs.nih.gov/dr2/index.cfm/resource/24278>).

### 14 SARS-CoV-2 Testing and COVID-19 Symptoms

15 To obtain data on COVID-19 history, diagnosis, and symptoms, researchers self-designed  
16 questions to assess overall health status prior to initial COVID-19 illness, history of SARS-CoV-  
17 2 testing and results, initial symptom onset date, symptoms experienced during the acute phase  
18 of COVID-19, new/continuing COVID-19 symptoms, impact of each reported symptom on daily  
19 activities, and self-reported recovery from COVID-19 illness. Participants without a history of  
20 infection are asked about health status prior to the COVID-19 pandemic, symptoms experienced  
21 in reference to overall general health, and self-reported recovery from the effects of the COVID-  
22 19 pandemic.

### 29 Vaccines and SARS-CoV-2 Re-infection

30 To collect data on vaccination and SARS-CoV-2 re-infection, researchers self-designed  
31 questions related to flu vaccination uptake, COVID-19 vaccination uptake, SARS-CoV-2  
32 antibody testing, participation in COVID-19 treatment trials, SARS-CoV-2 re-infection, and self-  
33 reported comparison of COVID-19 symptoms experienced during the first re-infection compared  
34 to initial illness. Participants without a history of infection are asked questions related to flu and  
35 COVID-19 vaccination uptake.

### 42 Treatments and Hospitalizations

43 Researchers self-designed questions to obtain data on medications used to treat initial  
44 COVID-19 illness, medications used to treat new/continuing COVID-19 symptoms, COVID-19  
45 related hospitalizations, health care utilization, and health seeking behavior to treat symptoms.  
46 In this section, participants without a history of infection are asked about overall health care  
47 utilization.

### 52 Pre-existing Comorbidities

1  
2  
3 In order to obtain data on pre-existing health status and comorbidities, researchers self-  
4 designed questions to capture current health status, pre-existing health conditions, cancer  
5 diagnosis, height, weight, current stress level, and stress level prior to the COVID-19 pandemic.  
6  
7

### 8 9 Physical Limitations & Exercise

10 To assess physical limitations and exercise, researchers utilized questions adapted from the  
11 Baltimore Longitudinal Study of Aging and the Godin-Shephard Leisure-Time Physical Activity  
12 Questionnaire.  
13  
14

15 The Baltimore Longitudinal Study of Aging (BLSA) is a longitudinal study of healthy adults  
16 with the aim of understanding how adults adjust to the aging process, including adjustments in  
17 physical activity.(17,18) During the baseline survey, participants are asked questions to assess  
18 difficulty and level of difficulty in the following domains: mobility (walking a quarter mile/one mile  
19 and going up 10 steps/20 steps) and instrumental activities of daily living (IADL) (light and heavy  
20 housework). If a participant reports experiencing difficulty, they are asked to report the level of  
21 difficulty (a little, some, a lot, or unable to do); conversely, if they do not report difficulty, they are  
22 asked to report the level of ease (very easy, somewhat easy, or not so easy).(17,18)  
23 Participants who report difficulty are also asked if they experienced the difficulty prior to their  
24 COVID-19 illness or the COVID-19 pandemic. For mobility, if a participant reports any level of  
25 difficulty walking a quarter of a mile, they are considered to have a mobility disability. For IADL,  
26 if a participant reports any level of difficulty with light housework, they are considered to have an  
27 IADL disability.  
28  
29  
30  
31  
32  
33  
34  
35

36 The Godin-Shephard Leisure-Time Physical Activity Questionnaire (GSLTPAQ) was  
37 validated for use in healthy adults by measuring the correlation between objective measures of  
38 physical condition, maximum oxygen intake during exercise ( $\dot{V}O_2$  max) and body fat percentile,  
39 and subjective measures of total leisure time physical activity.(19–21) The questionnaire was  
40 found to have a test-retest reliability of 0.94, 0.46, and 0.48 for strenuous, moderate, and light  
41 intensity exercise, respectively, with the highest correlation shown between  $\dot{V}O_2$  max and  
42 strenuous intensity exercise (Pearson's  $r = 0.38$ ) and body fat percentile and strenuous intensity  
43 exercise (Pearson's  $r = 0.21$ ).<sup>(20)</sup>  
44  
45  
46  
47  
48

49 During the baseline survey, participants are asked to report the number of times on average  
50 they participate in mild, moderate, and strenuous intensity exercise for longer than 15 minutes  
51 during a typical week. The number of times per week is multiplied by the corresponding  
52 Metabolic Equivalent of Task (MET) factor (3, 5, and 9 for mild, moderate, and strenuous  
53 intensity exercise, respectively) and summed for a total leisure activity score.(19,20) A score of  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  $\geq 24$  indicates an active lifestyle, a score of 14-23 indicates a moderately active lifestyle, and a  
4 score of  $< 14$  indicates an insufficiently active/sedentary lifestyle.(19) Participants with a history  
5 of infection are asked to report the number of times they exercised in each category before and  
6 after their COVID-19 illness; participants without a history of infection are asked in reference to  
7 before and after the COVID-19 pandemic.  
8  
9  
10

### 11 12 Sleep Quality

13  
14 Sleep quality is assessed using questions adapted from the AIDS Linked to the IntraVenous  
15 Experience (ALIVE) Study and the Idiopathic Hypersomnia Severity Scale. The ALIVE study is a  
16 prospective cohort study designed to characterize the incidence and natural history of HIV  
17 infection among injection drug users in Baltimore, MD.(22) Participants are asked how often  
18 they experience a list of five items related to sleep quality over the past four weeks. For each  
19 item, participants respond based on the following scale: 1 (all of the time), 2 (most of the time),  
20 3 (a good bit of the time), 4 (some of the time), 5 (a little bit of the time), or 6 (none of the time).  
21  
22

23  
24 The Idiopathic Hypersomnia Severity Scale (IHHS) was validated for use in patients  
25 experiencing three major symptoms of idiopathic hypersomnia: excessive daytime sleepiness,  
26 prolonged nighttime sleep, and sleep inertia, and was found to have high internal consistency  
27 (Cronbach  $\alpha = .89$ ) and good content validity.(23,24) The scale consists of 14 items and each  
28 item is scored separately and then summed together for a total score ranging from 0-50. Higher  
29 scores represent more severe/frequent symptoms of idiopathic hypersomnia.(23,24) For the  
30 purpose of the JHCLS, researchers utilized four questions from the IHHS for a range of scores  
31 from 0-14.  
32  
33

### 34 35 36 37 38 39 Mental Fatigue

40  
41 Mental fatigue is assessed using the Wood Mental Fatigue Inventory (WMFI). The WMFI  
42 has been validated for use in patients with Myalgic Encephalomyelitis/Chronic Fatigue  
43 Syndrome (ME/CFS) and was found to have high internal consistency (Cronbach  $\alpha = .93$ ) and  
44 good test-retest reliability (Pearson's  $r = 0.887$ ). (25) Participants are asked how much they have  
45 been bothered by a list of nine items over the past two weeks. Each item is scored on the  
46 following scale: 0 (not at all), 1 (a little), 2 (somewhat), 3 (quite a lot), or 4 (very much). At the  
47 end of the assessment, the scores are summed together for a range of 0-36. Higher scores  
48 indicate greater levels of mental fatigue.(25)  
49  
50  
51  
52

### 53 54 55 56 57 58 59 60 Anxiety

To assess anxiety, researchers utilize the Generalized Anxiety Disorder-7 (GAD-7). The GAD-7 has been validated for use in the general population and was found to have both high internal consistency (Cronbach  $\alpha = .92$ ) and good criterion, construct, factorial, and procedural validity.<sup>(26)</sup> Participants are asked how often they have been bothered by a list of seven items over the past two weeks. For each item, participants are scored based on the following scale: 0 (not at all), 1 (several days), 2 (more than half the days), or 3 (nearly every day). At the end of the assessment, the scores are summed together for a range of 0-21. A score of 0-4 indicates no anxiety disorder, a score of 5-9 indicates a mild anxiety disorder, a score of 10-14 indicates a moderate anxiety disorder, and a score of  $\geq 15$  indicates a severe anxiety disorder.<sup>(26)</sup>

### Demographics

Researchers self-designed survey questions to obtain demographic information, including gender, race/ethnicity, country of residence, year of birth, educational attainment, work activities prior to the COVID-19 pandemic, primary occupation, total household income, and total number of dependents.

### Patient and public involvement

There was no patient or public involvement in the design, conduct, reporting, or dissemination plans of our research. However, patient feedback is routinely discussed and considered. Specifically, patients are encouraged to reach out to study team members with suggestions on ways to improve the survey and the survey has been adjusted several times based on patient suggestions. In addition, study findings are regularly disseminated to patients via quarterly study newsletters posted on the study website ([www.covid-long.com](http://www.covid-long.com)).

### Baseline characteristics of JHCLS participants

Among 16,764 participants with a history of SARS-CoV-2 infection and defined long COVID status, the median age was 43 years, 84% were female, 88% self-reported white race, and 8.0% self-reported Hispanic/Latino ethnicity (Table 1). In terms of socioeconomic status, 70% of participants self-reported a bachelor's degree or higher and 72% self-reported an annual household income of greater than or equal to \$50,000. A diverse array of self-reported pre-existing comorbid conditions were reported, including hypertension (15%), depression/anxiety/other mental health conditions (35%), asthma/reactive airway disease/chronic lung disease (16%), and autoimmune disorders (9.6%) (Table 2). In addition, the majority of participants (65%) were classified as overweight/obese based on a calculated BMI of  $\geq 25$ .

1  
2  
3 Prior to COVID-19 illness, 75% of participants reported very good/excellent health status  
4 and 8.2% of participants reported fair/poor health status (Table 2). During the acute phase of  
5 COVID-19 illness, 99% of participants reported experiencing at least one symptom. Of those,  
6 90% reported cardiopulmonary symptoms (e.g., new/worsening cough, shortness of breath,  
7 rapid heart rate), 89% reported systemic symptoms (e.g., fatigue, muscle weakness, fever),  
8 85% reported neuropsychiatric symptoms (e.g., headache, dizziness, neuropathy), and 55%  
9 reported gastrointestinal symptoms (e.g., vomiting, diarrhea, lack of appetite). Overall, 9.9% of  
10 participants self-reported being hospitalized for their COVID-19 illness and 63% were defined as  
11 having long COVID based on the WHO definition.  
12

13  
14 At the time of study enrollment, 39% of participants with a history of infection reported not  
15 being vaccinated against SARS-CoV-2 compared to 56% who reported receiving at least a  
16 complete first vaccination series (Table 2). The median number of days between initial SARS-  
17 CoV-2 infection and study enrollment was 173 days. While most participants reported  
18 experiencing their initial SARS-CoV-2 infection in 2020 (56%), 29% reported being infected in  
19 2021, and 16% reported being infected in 2022.  
20

21  
22 Similar characteristics were found in participants without a history of SARS-CoV-2 infection  
23 who completed the baseline survey. Among 799 participants, the median age was 42, 85%  
24 were female, 82% self-reported white race, and 5.9% self-reported Hispanic/Latino ethnicity  
25 (Table 1). A higher percentage of participants without a history of infection self-reported 'other'  
26 race (13% compared to 5.4%) which was largely due to a greater number self-reporting  
27 Asian/Pacific Islander/Native Hawaiian race. With regard to socioeconomic status, a higher  
28 percentage of participants without a history of infection reported a bachelor's degree or higher  
29 (84% compared to 70%) and 72% reported an annual household income of \$50,000 or more.  
30 Comparable pre-existing comorbid conditions were reported: hypertension (13%),  
31 depression/anxiety/other mental health conditions (36%), asthma/reactive airway  
32 disease/chronic lung disease (12%), and autoimmune disorders (8.1%) (Table 2). Based on  
33 calculated BMI, a slightly higher percentage of participants without a history of infection were  
34 classified as having a normal BMI (43% compared to 34%).  
35

36  
37 Of participants without a history of SARS-CoV-2 infection, 75% reported very good/excellent  
38 health status and 7.5% reported fair/poor health status prior to the COVID-19 pandemic (Table  
39 2). At time of study enrollment, a higher percentage of participants without a history of infection  
40 reported at least a complete first vaccination series (97% compared to 56%). It is worth noting  
41 that enrollment for participants without a history of infection opened up in March 2022 when  
42 vaccinations were more widely available, likely accounting for this difference.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

The demographic and clinical characteristics between those who agreed to be contacted for future studies and those who declined were comparable, with the exception of long COVID status (Supplementary Table 2). Unsurprisingly, more individuals who fully recovered declined continued participation in the study. However, the number of indeterminate individuals (too early to determine long COVID status) was similar.

**Table 1** Baseline demographic characteristics of United States participants in the Johns Hopkins COVID Long Study

	Study Sample with SARS-CoV-2 Infection: Baseline Data <sup>1,2,3</sup> (n = 16,764)	Study Sample without SARS-CoV-2 Infection: Baseline Data <sup>1,4</sup> (n = 799)
<b>Gender</b>		
Cisgender man	2,514 (15%)	104 (13%)
Cisgender woman	14,010 (84%)	674 (85%)
Transgender man	24 (0.1%)	2 (0.3%)
Transgender woman	14 (0.1%)	1 (0.1%)
Different identity	181 (1.1%)	16 (2.0%)
Missing	21	2
<b>Race</b>		
White	14,651 (88%)	651 (82%)
Black	489 (3.0%)	15 (1.9%)
Other	890 (5.4%)	100 (13%)
Mixed race	537 (3.2%)	24 (3.0%)
Missing	197	9
<b>Hispanic, Latino or Spanish origin</b>	1,323 (8.0%)	47 (5.9%)
Missing	122	5
<b>Median age, IQR</b>	43 (34,55)	42 (32,57)
Missing	45	3
<b>Educational attainment</b>		
High school, GED, or less	974 (5.8%)	30 (3.8%)
Some college, Associates/technical degree	4,150 (25%)	98 (12%)
Bachelor's degree	5,135 (31%)	241 (30%)
Post-graduate degree	6,461 (39%)	430 (54%)
Missing	44	0
<b>Annual household income</b>		
<\$25,000	1,588 (11%)	100 (14%)
\$25,000 - \$34,999	957 (6.7%)	42 (5.8%)
\$35,000 - \$49,999	1,486 (10%)	60 (8.3%)
\$50,000 - \$74,999	2,697 (19%)	118 (16%)
\$75,000 or greater	7,635 (53%)	405 (56%)
Missing	2,401	74
<b>Region</b>		
Northeast	3,159 (19%)	180 (23%)
Midwest	3,462 (21%)	141 (18%)
South	6,581 (39%)	281 (35%)
West	3,538 (21%)	197 (25%)
Missing	24	0

<sup>1</sup>Missing data were due to invalid data, “don’t know” responses, “refuse to answer” responses, and missing responses. Percentages do not add up to 100% due to missing data. The number of missing data varies due to participants dropping out of the survey at different sections.

<sup>2</sup>Baseline data in participants with a history of SARS-CoV-2 infection is as of October 20, 2022.

<sup>3</sup>Limited to participants with a defined long COVID status. Long COVID status was determined using the [WHO definition](#). 320 participants without a defined long COVID status were excluded: 283 provided an initial SARS-CoV-2 infection date before the first confirmed positive test in the United States (January 20, 2020), 28 provided an invalid SARS-CoV-2 infection date, nine did not provide a SARS-CoV-2 infection date nor report experiencing symptoms of COVID-19.

<sup>4</sup>Baseline data in participants without a history of SARS-CoV-2 infection is as of February 14, 2023.

**Table 2** Baseline clinical characteristics of United States participants in the Johns Hopkins COVID Long Study

	Study Sample with SARS-CoV-2 Infection: Baseline Data <sup>1,2</sup> (n = 16,764)	Study Sample without SARS-CoV-2 Infection: Baseline Data <sup>1,3</sup> (n = 799)
Body mass index (kg/m <sup>2</sup> )		
Underweight (<18.5)	285 (1.8%)	13 (1.6%)
Normal weight (18.5 – 24.9)	5,517 (34%)	342 (43%)
Overweight (25 – 29.9)	4,643 (29%)	216 (27%)
Obese (30 and above)	5,827 (36%)	225 (28%)
Missing	492	3
Comorbid conditions		
Diabetes	716 (4.4%)	32 (4.0%)
Cardiovascular disease/congestive heart failure	379 (2.3%)	24 (3.0%)
Hypertension	2,526 (15%)	105 (13%)
Chronic kidney disease	138 (0.8%)	6 (0.8%)
Cancer	392 (2.4%)	17 (2.1%)
Asthma/reactive airway disease/chronic lung disease	2,684 (16%)	99 (12%)
Overweight/obese	4,853 (30%)	187 (23%)
Autoimmune disorder	1,568 (9.6%)	65 (8.1%)
Stroke	116 (0.7%)	9 (1.1%)
Depression/anxiety/other mental health condition	5,730 (35%)	286 (36%)
Missing	388	0
Self-rated health status prior to COVID-19 <sup>4</sup>		
Excellent	6,297 (38%)	283 (35%)
Very good	6,192 (37%)	321 (40%)
Good	2,900 (17%)	135 (17%)
Fair	1,242 (7.4%)	53 (6.6%)
Poor	126 (0.8%)	7 (0.9%)
Missing	7	0
Vaccination status at time of enrollment		
None = 0	6,414 (39%)	22 (2.8%)
Partial vaccination	805 (4.9%)	4 (0.5%)
Complete first series	4,006 (24%)	93 (12%)
≥1 Booster	5,208 (32%)	679 (85%)
Missing	331	1
Timing of initial SARS-CoV-2 infection		
January - June 2020	3,804 (23%)	N/A
July - December 2020	5,484 (33%)	N/A
January - June 2021	2,216 (13%)	N/A
July - December 2021	2,629 (16%)	N/A
≥January 2022	2,631 (16%)	N/A



**Table 2** Baseline clinical characteristics of United States participants in the Johns Hopkins COVID Long Study

	Study Sample with SARS-CoV-2 Infection: Baseline Data <sup>1,2</sup> (n = 16,764)	Study Sample without SARS-CoV-2 Infection: Baseline Data <sup>1,3</sup> (n = 799)
Missing	0	N/A
Time between initial infection and survey completion in days (median (IQR))	173 (70,382)	N/A
Missing	0	N/A
Symptom status at initial COVID-19 illness		
Symptomatic	16,588 (99%)	N/A
Asymptomatic	175 (1.0%)	N/A
Missing	1	N/A
Presenting symptoms at initial COVID-19 illness		
Cardiopulmonary	15,140 (90%)	N/A
Neuropsychiatric	14,178 (85%)	N/A
Systemic	14,949 (89%)	N/A
Gastrointestinal	9,175 (55%)	N/A
Missing	0	N/A
Hospitalization status at initial COVID-19 illness		
Not hospitalized	14,839 (90%)	N/A
Hospitalized	1,627 (9.9%)	N/A
Missing	298	N/A
Long COVID status at survey completion <sup>5</sup>		
Has long COVID	10,518 (63%)	N/A
Does not have long COVID	1,246 (7.4%)	N/A
Cannot be determined <sup>6</sup>	5,000 (30%)	N/A

<sup>1</sup>Missing data were due to invalid data, “don’t know” responses, “refuse to answer” responses, and missing responses. Percentages do not add up to 100% due to missing data. The number of missing data varies due to participants dropping out of the survey at different sections.

<sup>2</sup>Baseline data in participants with a history of SARS-CoV-2 infection is as of October 20, 2022.

<sup>3</sup>Baseline data in participants without a history of SARS-CoV-2 infection is as of February 14, 2023.

<sup>4</sup>Participants with a history of SARS-CoV-2 infection were asked for self-rated health status prior to their COVID-19 illness. Participants without a history of SARS-CoV-2 infection were asked for self-rated health status prior to the COVID-19 pandemic.

<sup>5</sup>Limited to participants with a defined long COVID status. Long COVID status was determined using the [WHO definition](#). 320 participants without a defined long COVID status were excluded: 283 provided an initial SARS-CoV-2 infection date before the first confirmed positive test in the United States (January 20, 2020), 28 provided an invalid SARS-CoV-2 infection date, nine did not provide a SARS-CoV-2 infection date nor report experiencing symptoms of COVID-19.

<sup>6</sup>Long COVID status could not be determined because fewer than 12 weeks existed between initial SARS-CoV-2 infection and survey completion.

## STRENGTHS AND LIMITATIONS

The JHCLS is a large, online, prospective cohort study of adults with representation in 53 U.S. states and territories. The baseline survey collects comprehensive clinical and behavioral data, including data related to COVID-19 diagnosis and treatment, health history, pre-existing health conditions, and physical, mental, and cognitive limitations, and utilizes several reliable,

1  
2  
3 validated scales to assess outcomes and exploratory variables. Participants are given the option  
4 to complete a one-time, anonymous online survey or to consent to longitudinal follow-up at  
5 predefined time intervals (every 3-6 months). In addition, the overall participant burden is  
6 minimal.  
7  
8

9 A major strength of the JHCLS is that a positive SARS-CoV-2 test is not required to be  
10 eligible to participate. We recognize that testing is often limited or inaccessible, and thus require  
11 either a self-reported positive test or symptoms of COVID-19. In addition, our survey collects  
12 data on a wide range of organ systems using several different validated measures. Despite  
13 early studies focusing primarily on the respiratory symptoms associated with initial COVID-19  
14 illness (e.g., shortness of breath), we appreciate that the SARS-CoV-2 virus may have notable  
15 effects on other organ systems following the acute period of infection as well.  
16  
17  
18  
19

20 Another strength of the JHCLS is the inclusion of participants without a history of SARS-  
21 CoV-2 infection which provides a natural control group, while also allowing for the determination  
22 of the incidence of long COVID among those who report a SARS-CoV-2 infection during follow-  
23 up. Importantly, both samples are comparable in terms of sociodemographic variables and pre-  
24 existing health conditions. We also recognize that many of the heterogeneous symptoms  
25 reported as long COVID may reflect all of us collectively living through a pandemic (i.e., anxiety,  
26 depression). Thus, it is important that we compare those with and without infection to evaluate  
27 some of these outcomes during the same time frame (versus retrospective or historical  
28 controls).  
29  
30  
31  
32  
33

34 In addition, there are few longitudinal studies focused on post-acute outcomes of COVID-19.  
35 Longitudinal studies provide an opportunity to evaluate change over time in exposures and  
36 outcomes. The longitudinal collection of data on new/continuing COVID-19 symptoms at each  
37 time point during follow-up will allow for evaluation of resolution and persistence of symptoms  
38 over time, as well as the impact of re-infection, vaccination, and other health changes. To date,  
39 just under 7,000 participants have consented to participate in longitudinal follow-up and have  
40 completed their first follow-up survey.  
41  
42  
43  
44  
45

46 The JHCLS also has a few limitations. The reliance on self-reported clinical data may result  
47 in recall and measurement bias. A second limitation is the possibility of selection bias due to the  
48 fact that the survey must be completed using a smart device or computer with internet access.  
49 This may preclude participants from lower socioeconomic statuses from participating.  
50 Additionally, many individuals enroll many months after their acute infection when they already  
51 have long COVID. A potential selection bias would include increased likelihood of participation  
52 among those with more severe long COVID. However, it is important to note that the JHCLS  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 has a subset of individuals (n = 2,020) who enrolled during their acute infection (within four  
4 weeks of infection). Another limitation is the possibility of recall bias, especially among  
5 participants with a history of COVID-19 illness experiencing mental fatigue and/or other  
6 cognitive limitations at the time of survey completion. Finally, there is a risk that findings from  
7 the JHCLS are not generalizable as the majority of participants self-reported white race, female  
8 gender, and are from a higher socioeconomic status. To address this, we plan to do stratified-  
9 specific analyses that may be better representative of individuals within that same stratum.  
10 However, whether a study is representative or not depends not on demographics but on  
11 potential effect measure modifiers that may or may not include demographics.(27) Additionally,  
12 results that may not necessarily be generalizable in the effect estimate may still be  
13 generalizable in the direction of effect (e.g., protective or increased risk) of an exposure on  
14 outcome.(27)  
15  
16  
17  
18  
19  
20  
21  
22

### 23 **Future plans**

24 Moving forward, the JHCLS will continue to enroll additional participants with and without a  
25 history of SARS-CoV-2 infection and collect data from the baseline and longitudinal surveys.  
26 The study team is in the initial stages of analyzing the longitudinal data collected thus far,  
27 focusing on the progression and resolution of long COVID symptoms over time. In addition, the  
28 study team is planning a cluster analysis of both initial and new/continuing COVID-19 symptoms  
29 to help address the broad WHO definition of long COVID. We plan to do this by bringing  
30 together the rich symptom data we have in our study with data on the impact each reported  
31 symptom has on daily functioning. In the future, the study team may apply for funding to answer  
32 additional research questions and to continue following the longitudinal participants for a longer  
33 period of time.  
34  
35  
36  
37  
38  
39

40 The JHCLS has the potential to impact both our overall understanding of long COVID and  
41 our ability to identify subgroups of individuals for targeted interventions. We can also capture  
42 real-time changes by SARS-CoV-2 variants (based on calendar time), location (using geospatial  
43 data), birth/age cohorts, and/or vaccine data.  
44  
45  
46  
47  
48

### 49 **COLLABORATION**

50 The JHCLS invites researchers to contact the corresponding author for collaboration  
51 opportunities.  
52  
53

### 54 **Acknowledgements**

1  
2  
3 We would like to express our deepest appreciation to our participants for their dedication,  
4 unwavering commitment, and vulnerability in sharing their stories with us. We would also like to  
5 thank the REDCap team at the Johns Hopkins Bloomberg School of Public Health for their  
6 continued assistance and guidance. This endeavor would not have been possible without their  
7 help. Lastly, we'd like to acknowledge and thank our student researchers.  
8  
9  
10

### 11 **Author contributions**

12 B. Lau, P. Duggal, and S.H. Mehta conceived the original study concept and design and act  
13 as Co-Principal Investigators. They take responsibility for the integrity of the data. B. Lau, P.  
14 Duggal, S.H. Mehta, and E. Wentz were responsible for the acquisition of the data. E. Wentz  
15 prepared the first draft of this manuscript, under the supervision of B. Lau, P. Duggal, and S.H.  
16 Mehta. E. Wentz, Z. Ni, K. Yenokyan, C. Vergara, J. Pahwa, T. Kammerling, P. Xiao, P. Duggal,  
17 B. Lau, and S.H. Mehta were involved in reviewing the manuscript and contributing to critical  
18 revisions. Administrative and technical support was provided by E. Wentz, C. Vergara, Z. Ni, J.  
19 Pahwa, T. Kammerling, and P. Xiao.  
20  
21  
22  
23  
24  
25  
26  
27

### 28 **Funding**

29 The study is supported by the Johns Hopkins University COVID-19 Research Response  
30 Program (N/A) and in part by the Johns Hopkins University Center for AIDS Research  
31 (P30AI094189), which is supported by the following NIH Co-Funding and Participating Institutes  
32 and Centers: NIAID, NCI, NICHD, NHLBI, NIDA, NIA, NIGMS, NIDDK, NIMHD. The content is  
33 solely the responsibility of the authors and does not necessarily represent the official views of  
34 the NIH.  
35  
36  
37  
38  
39

### 40 **Competing interests**

41 S.H. Mehta receives materials support from Abbott Laboratories (not related to this study).  
42  
43

### 44 **Patient consent for publication**

45 Not applicable.  
46  
47

### 48 **Ethics approval**

49 The study protocol was approved and exempted by the Institutional Review Board at the  
50 Johns Hopkins Bloomberg School of Public Health (IRB00014874) on January 8, 2021.  
51  
52  
53

### 54 **Data sharing statement**

55 Not applicable.  
56  
57  
58  
59  
60

**Figure 1 legend**


Participants who agree to be contacted for future studies are asked to consider joining the longitudinal follow-up cohort 3-6 months after they complete the baseline survey. As of this report, not everyone who has agreed to be contacted for future studies has been invited to join the longitudinal follow-up cohort.

For peer review only

**REFERENCES**

1. Bourmistrova NW, Solomon T, Braude P, Strawbridge R, Carter B. Long-term effects of COVID-19 on mental health: A systematic review. *J Affect Disord*. 2022 Feb;299:118–25.
2. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. *Nat Med*. 2021 Apr;27(4):601–15.
3. Raman B, Bluemke DA, Lüscher TF, Neubauer S. Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. *Eur Heart J*. 2022 Mar 14;43(11):1157–72.
4. Montani D, Savale L, Noel N, Meyrignac O, Colle R, Gasnier M, et al. Post-acute COVID-19 syndrome. *Eur Respir Rev*. 2022 Mar 31;31(163):210185.
5. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. *Lancet Infect Dis*. 2022 Apr;22(4):e102–7.
6. Perlis RH, Santillana M, Ognyanova K, Safarpour A, Lunz Trujillo K, Simonson MD, et al. Prevalence and Correlates of Long COVID Symptoms Among US Adults. *JAMA Netw Open*. 2022 Oct 27;5(10):e2238804.
7. Van Kessel SAM, Olde Hartman TC, Lucassen PLBJ, Van Jaarsveld CHM. Post-acute and long-COVID-19 symptoms in patients with mild diseases: a systematic review. *Fam Pract*. 2022 Jan 19;39(1):159–67.
8. Domingo FR, Waddell LA, Cheung AM, Cooper CL, Belcourt VJ, Zuckermann AME, et al. Prevalence of long-term effects in individuals diagnosed with COVID-19: an updated living systematic review [Internet]. *Epidemiology*; 2021 Jun [cited 2023 Jun 28]. Available from: <http://medrxiv.org/lookup/doi/10.1101/2021.06.03.21258317>
9. Castanares-Zapatero D, Chalon P, Kohn L, Dauvrin M, Detollenaere J, Maertens De Noordhout C, et al. Pathophysiology and mechanism of long COVID: a comprehensive review. *Ann Med*. 2022 Dec 31;54(1):1473–87.
10. Rodriguez-Sanchez I, Rodriguez-Mañas L, Laosa O. Long COVID-19: The Need for an Interdisciplinary Approach. *Clin Geriatr Med*. 2022 Aug;38(3):533–44.
11. Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. *Nat Med*. 2022 May;28(5):911–23.
12. Ramakrishnan RK, Kashour T, Hamid Q, Halwani R, Tleyjeh IM. Unraveling the Mystery Surrounding Post-Acute Sequelae of COVID-19. *Front Immunol*. 2021 Jun 30;12:686029.
13. Pavli A, Theodoridou M, Maltezou HC. Post-COVID Syndrome: Incidence, Clinical Spectrum, and Challenges for Primary Healthcare Professionals. *Arch Med Res*. 2021 Aug;52(6):575–81.
14. Karuna S, Gallardo-Cartagena JA, Theodore D, Hunidzarira P, Montenegro-Idrogo J, Hu J, et al. Post-COVID symptom profiles and duration in a global convalescent COVID-19 observational cohort: Correlations with demographics, medical history, acute COVID-19 severity and global region. *J Glob Health*. 2023 Jun 23;13:06020.

15. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform.* 2009 Apr;42(2):377–81.
16. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: Building an international community of software platform partners. *J Biomed Inform.* 2019 Jul;95:103208.
17. Ferrucci L. The Baltimore Longitudinal Study of Aging (BLSA): a 50-year-long journey and plans for the future. *J Gerontol A Biol Sci Med Sci.* 2008 Dec;63(12):1416–9.
18. Stone JL, Norris AH. Activities and Attitudes of Participants in the Baltimore Longitudinal Study. *J Gerontol.* 1966 Oct 1;21(4):575–80.
19. Gaston Godin. The Godin--Shephard Leisure--Time Physical Activity Questionnaire. *Health Fit J Can.* 2011;4(1):18–22.
20. Godin G, Shephard RJ. A simple method to assess exercise behavior in the community. *Can J Appl Sport Sci J Can Sci Appl Au Sport.* 1985 Sep;10(3):141–6.
21. Amireault S, Godin G. The Godin-Shephard Leisure-Time Physical Activity Questionnaire: Validity Evidence Supporting its Use for Classifying Healthy Adults into Active and Insufficiently Active Categories. *Percept Mot Skills.* 2015 Apr;120(2):604–22.
22. Vlahov D, Anthony JC, Munoz A, Margolick J, Nelson KE, Celentano DD, et al. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. *NIDA Res Monogr.* 1991;109:75–100.
23. Rassu AL, Evangelista E, Barateau L, Chenini S, Lopez R, Jaussent I, et al. Idiopathic Hypersomnia Severity Scale to better quantify symptoms severity and their consequences in idiopathic hypersomnia. *J Clin Sleep Med.* 2022 Feb;18(2):617–29.
24. Dauvilliers Y, Evangelista E, Barateau L, Lopez R, Chenini S, Delbos C, et al. Measurement of symptoms in idiopathic hypersomnia: The Idiopathic Hypersomnia Severity Scale. *Neurology.* 2019 Apr 9;92(15):e1754–62.
25. Bentall RP, Wood GC, Marrinan T, Deans C, Edwards RHT. A brief mental fatigue questionnaire. *Br J Clin Psychol.* 1993 Sep;32(3):375–7.
26. Spitzer RL, Kroenke K, Williams JBW, Löwe B. A Brief Measure for Assessing Generalized Anxiety Disorder: The GAD-7. *Arch Intern Med.* 2006 May 22;166(10):1092.
27. Jacqueline E Rudolph, Yongqi Zhong, Priya Duggal, Shruti H Mehta, Bryan Lau. Defining representativeness of study samples in medical and population health research. *BMJ Med.* 2023 May 1;2(1):e000399.



45 Participants who agree to be contacted for future studies are asked to consider joining the longitudinal  
 46 follow-up cohort 3-6 months after they complete the baseline survey. As of this report, not everyone who  
 47 has agreed to be contacted for future studies has been invited to join the longitudinal follow-up cohort.

48 189x231mm (300 x 300 DPI)



**Supplementary Table 1** Survey measures

Domain	Questionnaire	Variable Description	Validation	Scoring
SARS-CoV-2 Testing and COVID-19 Symptoms	Self-designed	General health before COVID-19 illness (population with history of SARS-CoV-2 infection) or COVID-19 pandemic (population without history of SARS-CoV-2 infection), SARS-CoV-2 testing (number of times, result, exposure, test type, month/year of first positive test), month/year of initial symptom onset, symptoms experienced during initial illness, new/continuing symptoms experienced after initial illness, impact of each symptom on daily activities, self-reported recovery compared to before COVID-19 illness (population with history of SARS-CoV-2 infection) or COVID-19 pandemic (population without history of SARS-CoV-2 infection), new physician diagnoses since COVID-19 illness (population with history of SARS-CoV-2 infection) or COVID-19 pandemic (population without history of SARS-CoV-2 infection)	N/A	Categorical responses
Vaccines and SARS-CoV-2 Re-infection	Self-designed	Flu vaccine uptake, COVID-19 vaccine uptake (number of doses, series type, month/year per dose), SARS-CoV-2 antibody testing (month/year of testing, result), COVID-19 treatment trials, COVID-19 re-infection (number of times, exposure, test type, month/year of each positive test, month/year of each symptom onset), comparison of first re-infection to initial infection	N/A	Categorical responses
COVID-19 Treatments and Hospitalizations	Self-designed	Treatments for COVID-19, treatments for new/continuing COVID-19 symptoms, hospitalizations (number of days, severity), health care utilization (pre-COVID-19 illness and current), health seeking behavior to treat symptoms	N/A	Categorical responses
Comorbidities	Self-designed	Self-reported current health status, pre-existing health conditions, cancer diagnosis (type, diagnosis timeframe, treatments), height, weight, current stress level, stress level before the COVID-19 pandemic	N/A	Categorical responses

<b>Supplementary Table 1 Continued</b>				
<b>Domain</b>	<b>Questionnaire</b>	<b>Variable Description</b>	<b>Validation</b>	<b>Scoring</b>
Limitations and Exercise	Baltimore Longitudinal Study of Aging(17,18)	Overall physical limitations before COVID-19 illness (population with history of SARS-CoV-2 infection) or COVID-19 pandemic (population without history of SARS-CoV-2 infection), difficulty walking a quarter of a mile/one mile, difficulty walking up 10 steps/20 steps, difficulty with performing light housework/heavy housework, difficulty level (if difficulty reported), level of ease (if no difficulty reported), indicator for incident/prevalent disability	N/A	<p><u>Mobility disability</u>: Any level of difficulty walking a quarter of a mile</p> <p><u>Instrumental activities of daily living disability</u>: Any level of difficulty with light housework</p>
	Godin-Shephard Leisure-Time Physical Activity Questionnaire(19–21)	Number of times in a typical week doing strenuous, moderate, and mild intensity exercise for more than 15 minutes before and after COVID-19 illness (population with history of SARS-CoV-2 infection) or COVID-19 pandemic (population without history of SARS-CoV-2 infection)	<p>Validated in population of healthy adults</p> <p>Test-retest reliability: 0.94 for strenuous exercise, 0.46 for moderate exercise, and 0.48 for light exercise</p>	<p>1) Multiply number of times per week per category by Metabolic Equivalent of Task factor (3 for light, 5 for moderate, 9 for strenuous)</p> <p>2) Sum scores for total leisure time activity score</p> <ul style="list-style-type: none"> <li>• <math>\geq 24</math>: active lifestyle</li> <li>• 14-23: moderately active lifestyle</li> <li>• <math>&lt; 14</math>: sedentary lifestyle</li> </ul>
Sleep Quality	AIDS Linked to the IntraVenous Experience (ALIVE) Study(22)	Total hours slept in typical 24-hour period, overall sleep quality during last four weeks, insomnia (difficulty falling/staying asleep)	N/A	Categorical responses
	Idiopathic Hypersomnia Severity Scale(23,24)	Four indicators of hypersomnia (assessment of sleep adequacy, difficulty waking up, length of time to feel fully functioning upon waking, struggling to stay awake during the day)	<p>Validated in patients experiencing idiopathic hypersomnia</p> <p>High internal consistency (Cronbach <math>\alpha = .89</math>) and good content validity</p>	<p>1) Each item is assigned a score (0-3 or 0-4)</p> <p>2) Sum scores for a total of 0-14</p> <p>Higher scores represent more severe/frequent symptoms of idiopathic hypersomnia</p>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

<b>Supplementary Table 1</b> Continued				
<b>Domain</b>	<b>Questionnaire</b>	<b>Variable Description</b>	<b>Validation</b>	<b>Scoring</b>
Cognition	Wood Mental Fatigue Inventory (WMFI)(25)	Nine indicators of mental fatigue over last two weeks (confusion, mixed thoughts, poor concentration, difficulty with decision making, memory problems, issues taking things in, slow thoughts, muzzy head, issues finding words)	Validated in patients with ME/CFS  High internal consistency (Cronbach $\alpha$ =.93) and good test-retest reliability (Pearson's $r$ = 0.887)	1) Each item is assigned a score from 0-4  2) Sum scores for total of 0-36  Higher scores indicate greater levels of mental fatigue
Anxiety	Generalized Anxiety Disorder-7 (GAD-7)(26)	Seven indicators of anxiety over last two weeks (feeling anxious, not able to control worrying, worrying about different things, trouble relaxing, restlessness, irritability, feeling afraid)	Validated in general population  High internal consistency (Cronbach $\alpha$ =.92)  Good criterion, construct, factorial, and procedural validity	1) Each item is assigned a score from 0-3  2) Sum scores for total of 0-21  <ul style="list-style-type: none"> <li>• 0-4: no anxiety disorder</li> <li>• 5-9: mild anxiety disorder</li> <li>• 10-14: moderate anxiety disorder</li> <li>• <math>\geq</math>15: severe anxiety disorder</li> </ul>
Demographics	Self-designed	Work activities prior to the COVID-19 pandemic, primary occupation, household income in 2019, number of dependents	N/A	Categorical responses

**Supplementary Table 2** Comparison of baseline demographic and clinical characteristics among participants with SARS-CoV-2 infection who agreed and declined to be contacted for future studies<sup>1,2,3,4</sup>

	Agreed to be Contacted for Future Studies (n = 11,924)	Declined to be Contacted for Future Studies (n = 3,554)
<b>Gender</b>		
Cisgender man	1,829 (15%)	510 (14%)
Cisgender woman	9,934 (83%)	2,992 (84%)
Transgender man	15 (0.1%)	6 (0.2%)
Transgender woman	11 (0.1%)	1 (<0.1%)
Different identity	127 (1.1%)	36 (1.0%)
Missing	8	9
<b>Race</b>		
White	10,538 (89%)	3,067 (88%)
Black	348 (2.9%)	88 (2.5%)
Other	563 (4.8%)	213 (6.1%)
Mixed race	384 (3.3%)	117 (3.4%)
Missing	91	69
Hispanic, Latino or Spanish origin	892 (7.5%)	289 (8.2%)
Missing	68	35
<b>Median age, IQR</b>	46 (36,57)	42 (33,52)
Missing	34	6
<b>Educational attainment</b>		
High school, GED, or less	620 (5.2%)	243 (6.9%)
Some college, Associates/technical degree	3,009 (25%)	823 (23%)
Bachelor's degree	3,601 (30%)	1,116 (32%)
Post-graduate degree	4,676 (39%)	1,356 (38%)
Missing	18	16
<b>Annual household income</b>		
<\$25,000	1,163 (11%)	394 (13%)
\$25,000 - \$34,999	712 (6.5%)	227 (7.4%)
\$35,000 - \$49,999	1,125 (10%)	328 (11%)
\$50,000 - \$74,999	2,084 (19%)	576 (19%)
\$75,000 or greater	5,939 (54%)	1,540 (50%)
Missing	901	489
<b>Region</b>		
Northeast	2,216 (19%)	679 (19%)
Midwest	2,383 (20%)	810 (23%)
South	4,790 (40%)	1,290 (36%)
West	2,522 (21%)	766 (22%)
Missing	13	9
<b>Hospitalization status at initial COVID-19 illness</b>		
Not hospitalized	10,612 (89%)	3,305 (93%)
Hospitalized	1,304 (11%)	245 (6.9%)
Missing	8	4
<b>Comorbid conditions</b>		
Diabetes	561 (4.7%)	119 (3.4%)
Cardiovascular disease/congestive heart failure	287 (2.4%)	68 (1.9%)
Hypertension	1,930 (16%)	492 (14%)
Chronic kidney disease	97 (0.8%)	32 (0.9%)
Cancer	306 (2.6%)	71 (2.0%)
Asthma/reactive airway disease/chronic lung disease	2,077 (17%)	485 (14%)

**Supplementary Table 2** Comparison of baseline demographic and clinical characteristics among participants with SARS-CoV-2 infection who agreed and declined to be contacted for future studies<sup>1,2,3,4</sup>

	Agreed to be Contacted for Future Studies (n = 11,924)	Declined to be Contacted for Future Studies (n = 3,554)
Overweight/obese	3,670 (31%)	969 (27%)
Autoimmune disorder	1,203 (10%)	297 (8.4%)
Stroke	93 (0.8%)	14 (0.4%)
Depression/anxiety/other mental health condition	4,262 (36%)	1,171 (33%)
Missing	1	0
Long COVID status at survey completion		
Has long COVID	7,698 (65%)	2,069 (58%)
Does not have long COVID	693 (5.8%)	421 (12%)
Cannot be determined <sup>4</sup>	3,533 (30%)	1,064 (30%)

<sup>1</sup>Missing data were due to invalid data, “don’t know” responses, “refuse to answer” responses, and missing responses. Percentages do not add up to 100% due to missing data. The number of missing data varies due to participants dropping out of the survey at different sections.

<sup>2</sup>Baseline data in participants with a history of SARS-CoV-2 infection is as of October 20, 2022.

<sup>3</sup>Limited to participants with a defined long COVID status. Long COVID status was determined using the [WHO definition](#). 320 participants without a defined long COVID status were excluded: 283 provided an initial SARS-CoV-2 infection date before the first confirmed positive test in the United States (January 20, 2020), 28 provided an invalid SARS-CoV-2 infection date, nine did not provide a SARS-CoV-2 infection date nor report experiencing symptoms of COVID-19.

<sup>4</sup>Long COVID status could not be determined because fewer than 12 weeks existed between initial SARS-CoV-2 infection and survey completion.

# BMJ Open

## Cohort profile: the Johns Hopkins COVID Long Study (JHCLS), a United States Nationwide Prospective Cohort Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-077742.R2
Article Type:	Cohort profile
Date Submitted by the Author:	14-Feb-2024
Complete List of Authors:	Wentz, Eryka; Johns Hopkins University Bloomberg School of Public Health, Epidemiology Ni, Zhanmo; Johns Hopkins School of Medicine, Oncology Yenokyan, Karine; Johns Hopkins University Bloomberg School of Public Health, Epidemiology Vergara, Candelaria; Johns Hopkins University Bloomberg School of Public Health, Epidemiology Pahwa, Jessica; Johns Hopkins University Bloomberg School of Public Health, Epidemiology Kammerling, Thea; Johns Hopkins University Bloomberg School of Public Health, Epidemiology Xiao, Pu; Johns Hopkins University Whiting School of Engineering, Data Science Duggal, Priya; Johns Hopkins University Bloomberg School of Public Health, Epidemiology Lau, Bryan; Johns Hopkins University Bloomberg School of Public Health, General Epidemiology and Methodology Mehta, Shruti; Johns Hopkins University Bloomberg School of Public Health, Epidemiology
<b>Primary Subject Heading</b>:	Epidemiology
Secondary Subject Heading:	Infectious diseases
Keywords:	COVID-19, INFECTIOUS DISEASES, Chronic Disease, EPIDEMIOLOGIC STUDIES

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Cohort profile: the Johns Hopkins COVID Long Study (JHCLS), a United States**  
4 **Nationwide Prospective Cohort Study**  
5

6 Eryka Wentz, MA, Zhanmo Ni, MHS, Karine Yenokyan, PhD, Candelaria Vergara, MD, Jessica  
7 Pahwa, MPH, Thea Kammerling, BA, Pu Xiao, BS, Priya Duggal, PhD, Bryan Lau, PhD, Shruti  
8 H. Mehta, PhD  
9

10 **Corresponding author:** Eryka Wentz, 615 N. Wolfe Street, Baltimore, MD 21205,  
11 [ewentz1@jhu.edu](mailto:ewentz1@jhu.edu), (410) 834-1603 (phone), (410) 614-0902 (fax)  
12

13  
14 **Eryka Wentz**, Johns Hopkins Bloomberg School of Public Health, Baltimore, United States of  
15 America

16 **Zhanmo Ni**, Johns Hopkins School of Medicine, Baltimore, United States of America

17 **Karine Yenokyan**, Johns Hopkins Bloomberg School of Public Health, Baltimore, United States  
18 of America

19 **Candelaria Vergara**, Johns Hopkins Bloomberg School of Public Health, Baltimore, United  
20 States of America

21 **Jessica Pahwa**, Johns Hopkins Bloomberg School of Public Health, Baltimore, United States of  
22 America

23 **Thea Kammerling**, Johns Hopkins Bloomberg School of Public Health, Baltimore, United  
24 States of America

25 **Pu Xiao**, Johns Hopkins Whiting School of Engineering, Baltimore, United States of America

26 **Priya Duggal**, Johns Hopkins Bloomberg School of Public Health, Baltimore, United States of  
27 America

28 **Bryan Lau**, Johns Hopkins Bloomberg School of Public Health, Baltimore, United States of  
29 America

30 **Shruti H. Mehta**, Johns Hopkins Bloomberg School of Public Health, Baltimore, United States  
31 of America  
32

33  
34 **Keywords:** COVID-19, SARS-CoV-2, Infectious Diseases, Chronic Disease, Epidemiologic  
35 Studies  
36

37 **Word count:** 4,473  
38

39  
40 **ABSTRACT**  
41

42 **Purpose** COVID-19 disease continues to affect millions of individuals worldwide, both in the  
43 short and long term. The post-acute complications of SARS-CoV-2 infection, referred to as long  
44 COVID, result in diverse symptoms affecting multiple organ systems. Little is known regarding  
45 how the symptoms associated with long COVID progress and resolve over time. The Johns  
46 Hopkins COVID Long Study aims to prospectively examine the short- and long-term  
47 consequences of COVID-19 disease in individuals both with and without a history of SARS-  
48 CoV-2 infection using self-reported data collected in an online survey.  
49

50 **Participants** Sixteen thousand, seven hundred sixty-four adults with a history of SARS-CoV-2  
51 infection and 799 adults without a history of SARS-CoV-2 infection who completed an online  
52 baseline survey.  
53

54 **Findings to date** This cohort profile describes the baseline characteristics of the Johns  
55 Hopkins COVID Long Study. Among 16,764 participants with a history of SARS-CoV-2 infection  
56  
57  
58  
59  
60



1  
2  
3 and defined long COVID status, 75% reported a good or excellent health status prior to  
4 infection, 99% reported experiencing at least one COVID-19 symptom during the acute phase of  
5 infection, 9.9% reported a hospitalization, and 63% were defined as having long COVID using  
6 the WHO definition.  
7

8 **Future plans** Analysis of longitudinal data will be used to investigate the progression and  
9 resolution of long COVID symptoms over time.  
10

## 11 12 13 14 **ARTICLE SUMMARY**

### 15 16 **Strengths and limitations of this study**

- 17  
18 • The Johns Hopkins COVID Long Study (JHCLS) is a large, online, prospective cohort study of  
19 adults that collects comprehensive clinical and behavioral data on participants with and  
20 without a history of SARS-CoV-2 infection at baseline with an option to participate in  
21 longitudinal follow-up every 3-6 months.  
22
- 23 • Detailed clinical data are collected on COVID-19 diagnosis and treatment, health history, and  
24 pre-existing health conditions, in addition to validated measurements on physical, mental, and  
25 cognitive limitations.  
26
- 27 • The JHCLS is comprised of participants from 53 United States and territories and includes  
28 individuals aged 19-96 years.  
29
- 30 • Because SARS-CoV-2 tests are not always accessible, eligibility requirements include either  
31 a self-reported positive SARS-CoV-2 test or symptoms of COVID-19.  
32
- 33 • There may be selection and recall bias due to the increased likelihood of participation by  
34 individuals with long COVID and self-reported clinical data; however, the JHCLS is comprised  
35 of a subset of individuals who enrolled within four weeks of their initial SARS-CoV-2 infection  
36 and had not yet developed long COVID.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

Since its emergence in 2019, COVID-19 has greatly affected the health and well-being of millions of people worldwide.(1,2) Both acute and persistent post-infection complications have been reported by patients(3) and COVID-19 is now recognized as a multi-organ disease.(4) The World Health Organization (WHO) defines persistent post-infection complications, referred to as long COVID, as new or continuing symptoms three months after initial illness that last at least two months and cannot be explained otherwise.(5) Despite recent studies suggesting that long COVID may occur in 10-55% of individuals exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),(6–8) the exact incidence remains unknown. There is also uncertainty in the pathophysiology and symptomatology of long COVID.(9,10) With the elevated burden of COVID-19 worldwide, it is important to understand the full range of symptoms and long-term outcomes.(2) Moreover, the large number of individuals requiring continued medical care will pose an economic burden on our health care system.(10)

Similar to other infections, SARS-CoV-2 is associated with post-acute infection syndromes resulting in a variety of symptoms.(11) Some of the core symptoms associated with long COVID are common to other post-acute infection syndromes as well, including but not limited to fatigue, exertion intolerance, and neurocognitive impairment.(11) Despite our general knowledge of the occurrence of post-acute infection syndromes, it is largely understudied. Cohort studies composed of those who have had SARS-CoV-2 and those who have not (i.e., control population) are critical to understanding the gaps in our knowledge of long COVID and post-acute infections in general.

The presentation of those with long COVID is often marked with multiple diverse symptoms affecting multiple organs; each individual may have their own unique clinical presentation.(12) Though age is a major risk factor in COVID-19 related mortality, and despite a preponderance of long COVID among those aged 40 - 60 years, long COVID is reported across the age spectrum.(13) Similarly, long COVID is reported by persons of all genders, race/ethnicities, and those with and without pre-existing comorbidities.(13,14) Hence, it is essential that research both identifies and characterizes the main clinical and epidemiological features associated with long COVID, including potential targets for intervention.

For these reasons, the Johns Hopkins COVID Long Study (JHCLS) was established to prospectively examine the short- and long-term consequences of COVID-19 over a 3-year follow-up period. The overall objectives of the JHCLS are to (1) characterize the spectrum of long-term sequelae of SARS-CoV-2 infection; (2) identify individuals at risk for long-term sequelae; and (3) characterize the physical and mental health disability associated with long

COVID. To meet study objectives, the cohort includes participants with and without a history of SARS-CoV-2 infection. This cohort profile describes baseline demographic and clinical characteristics of United States (U.S.) participants enrolled in the JHCLS.

## COHORT DESCRIPTION

### Study design and participants

The JHCLS launched for participants with a self-reported history of SARS-CoV-2 infection on February 2, 2021, and expanded to include participants without a history of SARS-CoV-2 infection on March 2, 2022. All consenting participants are asked to complete a one-time, short online baseline survey with the option to remain anonymous. At the end of the baseline survey, participants are asked if they agree to be contacted for future COVID-19 studies, such as enrollment into longitudinal follow-up. If they respond yes, they are contacted by email or phone 3-6 months later with information about participating in longitudinal follow-up. If they subsequently consent to participate in longitudinal follow-up, they are emailed a follow-up survey every 3-6 months.

As of February 14, 2023, 20,319 participants with a self-reported history of SARS-CoV-2 infection and 1,041 participants without a history of SARS-CoV-2 infection consented to participate in the JHCLS (Figure 1). Of the 20,319 participants with a history of infection, 15,478 with a defined long COVID status (76%) completed the baseline survey and 11,924 (59%) consented to be contacted for future studies. Of these, 6,327 have enrolled in longitudinal follow-up and completed their first follow-up survey. Of the 1,041 participants without a history of infection, 799 (77%) completed the baseline survey and 501 (48%) consented to be contacted for future studies. Of these, 278 have enrolled in longitudinal follow-up and completed their first follow-up survey. At each round of follow-up, participants without a history of infection are asked if they have experienced COVID-19 symptoms or tested positive for SARS-CoV-2 since their last survey completion. If they respond yes, they are transferred to the survey for participants with a history of infection. As of February 14, 2023, 46 of the 278 participants (17%) who completed their first round of longitudinal follow-up have self-reported either a positive SARS-CoV-2 test or symptoms of COVID-19. The median survey completion time is 20 minutes for the baseline survey and 24 minutes for the first follow-up survey.

### Recruitment

1  
2  
3 Participants are recruited into the JHCLS using several mechanisms: social media posts,  
4 Facebook ad campaigns, direct messaging (e.g., emails to health departments), word of mouth,  
5 and participation in a recruitment registry. For social media recruitment, researchers utilize  
6 study-owned and operated Instagram, Facebook, and Twitter accounts. In addition, the team  
7 partnered with the Audience Development Team at the Johns Hopkins Bloomberg School of  
8 Public Health (BSPH) Communications Department to develop targeted Facebook ad  
9 campaigns. The study ran three Facebook ad campaigns, each targeting a neighborhood in the  
10 U.S. with high SARS-CoV-2 case counts. Two campaigns ran in April 2021, the first targeting  
11 neighborhoods in Detroit, Michigan, and the second in Fayetteville and Hope Mills, North  
12 Carolina, and South Fulton and Alpharetta, Georgia. The final campaign ran in July 2021 and  
13 targeted neighborhoods in Houston and San Antonio, Texas, Miami and Jacksonville, Florida,  
14 and Los Angeles, California.

15  
16  
17  
18  
19  
20  
21  
22 The study team also partners with the Johns Hopkins Opportunities for Participant  
23 Engagement (HOPE) Registry. The HOPE Registry (<http://johnshopkinshope.org/>) is a  
24 recruitment registry designed to connect individuals with teams conducting COVID-19 research  
25 studies at Johns Hopkins University. The JHCLS was officially enrolled into the HOPE Registry  
26 in April 2021.

### 27 28 29 30 31 **Participant eligibility**

32  
33 The JHCLS was approved and determined to be exempt by the Institutional Review Board  
34 (IRB) at the BSPH on January 8, 2021.

35  
36 To be eligible to participate in the study, participants must be at least 18 years of age.  
37 Additionally, to be eligible to complete the survey for participants with a history of SARS-CoV-2  
38 infection, participants must self-report at least one positive SARS-CoV-2 test or symptoms of  
39 COVID-19. At the start of the baseline survey, eligible participants are provided with a short,  
40 informed consent script that details the purpose of the study and provides details on  
41 participation. In order to protect the confidentiality of participants, participants are assigned a  
42 unique study identifier number and data are collected anonymously.

### 43 44 45 46 47 48 **Study procedures**

49  
50 The JHCLS baseline survey is self-administered and collects data across nine domains:  
51 SARS-CoV-2 testing and COVID-19 symptoms, vaccines and SARS-CoV-2 re-infection,  
52 COVID-19 treatments and hospitalizations, pre-existing comorbidities, physical limitations and  
53 exercise, sleep quality, mental fatigue, anxiety, and demographics (Supplementary Table 1).  
54 Data from these same domains are collected during longitudinal follow-up as well. All data are  
55  
56  
57  
58  
59  
60

1  
2  
3 collected in REDCap, a HIPAA-compliant, secure web application designed to build and  
4 manage online surveys and databases.(15,16) Most survey questions were adapted from  
5 validated measures and assessments. However, certain questions were self-designed for the  
6 purpose of meeting study objectives. All self-designed questionnaires are available on the  
7 National Institute of Environmental Health Sciences Disaster Research Response (DR2)  
8 Resources Portal (<https://tools.niehs.nih.gov/dr2/index.cfm/resource/24278>).

### 14 SARS-CoV-2 Testing and COVID-19 Symptoms

15 To obtain data on COVID-19 history, diagnosis, and symptoms, researchers self-designed  
16 questions to assess overall health status prior to initial COVID-19 illness, history of SARS-CoV-  
17 2 testing and results, initial symptom onset date, symptoms experienced during the acute phase  
18 of COVID-19, new/continuing COVID-19 symptoms, impact of each reported symptom on daily  
19 activities, and self-reported recovery from COVID-19 illness. Participants without a history of  
20 infection are asked about health status prior to the COVID-19 pandemic, symptoms experienced  
21 in reference to overall general health, and self-reported recovery from the effects of the COVID-  
22 19 pandemic.

### 29 Vaccines and SARS-CoV-2 Re-infection

30 To collect data on vaccination and SARS-CoV-2 re-infection, researchers self-designed  
31 questions related to flu vaccination uptake, COVID-19 vaccination uptake, SARS-CoV-2  
32 antibody testing, participation in COVID-19 treatment trials, SARS-CoV-2 re-infection, and self-  
33 reported comparison of COVID-19 symptoms experienced during the first re-infection compared  
34 to initial illness. Participants without a history of infection are asked questions related to flu and  
35 COVID-19 vaccination uptake.

### 42 Treatments and Hospitalizations

43 Researchers self-designed questions to obtain data on medications used to treat initial  
44 COVID-19 illness, medications used to treat new/continuing COVID-19 symptoms, COVID-19  
45 related hospitalizations, health care utilization, and health seeking behavior to treat symptoms.  
46 In this section, participants without a history of infection are asked about overall health care  
47 utilization.

### 52 Pre-existing Comorbidities

1  
2  
3 In order to obtain data on pre-existing health status and comorbidities, researchers self-  
4 designed questions to capture current health status, pre-existing health conditions, cancer  
5 diagnosis, height, weight, current stress level, and stress level prior to the COVID-19 pandemic.  
6  
7

### 8 9 Physical Limitations & Exercise

10 To assess physical limitations and exercise, researchers utilized questions adapted from the  
11 Baltimore Longitudinal Study of Aging and the Godin-Shephard Leisure-Time Physical Activity  
12 Questionnaire.  
13  
14

15 The Baltimore Longitudinal Study of Aging (BLSA) is a longitudinal study of healthy adults  
16 with the aim of understanding how adults adjust to the aging process, including adjustments in  
17 physical activity.(17,18) During the baseline survey, participants are asked questions to assess  
18 difficulty and level of difficulty in the following domains: mobility (walking a quarter mile/one mile  
19 and going up 10 steps/20 steps) and instrumental activities of daily living (IADL) (light and heavy  
20 housework). If a participant reports experiencing difficulty, they are asked to report the level of  
21 difficulty (a little, some, a lot, or unable to do); conversely, if they do not report difficulty, they are  
22 asked to report the level of ease (very easy, somewhat easy, or not so easy).(17,18)  
23 Participants who report difficulty are also asked if they experienced the difficulty prior to their  
24 COVID-19 illness or the COVID-19 pandemic. For mobility, if a participant reports any level of  
25 difficulty walking a quarter of a mile, they are considered to have a mobility disability. For IADL,  
26 if a participant reports any level of difficulty with light housework, they are considered to have an  
27 IADL disability.  
28  
29  
30  
31  
32  
33  
34  
35

36 The Godin-Shephard Leisure-Time Physical Activity Questionnaire (GSLTPAQ) was  
37 validated for use in healthy adults by measuring the correlation between objective measures of  
38 physical condition, maximum oxygen intake during exercise ( $\dot{V}O_2$  max) and body fat percentile,  
39 and subjective measures of total leisure time physical activity.(19–21) The questionnaire was  
40 found to have a test-retest reliability of 0.94, 0.46, and 0.48 for strenuous, moderate, and light  
41 intensity exercise, respectively, with the highest correlation shown between  $\dot{V}O_2$  max and  
42 strenuous intensity exercise (Pearson's  $r = 0.38$ ) and body fat percentile and strenuous intensity  
43 exercise (Pearson's  $r = 0.21$ ).<sup>(20)</sup>  
44  
45  
46  
47  
48

49 During the baseline survey, participants are asked to report the number of times on average  
50 they participate in mild, moderate, and strenuous intensity exercise for longer than 15 minutes  
51 during a typical week. The number of times per week is multiplied by the corresponding  
52 Metabolic Equivalent of Task (MET) factor (3, 5, and 9 for mild, moderate, and strenuous  
53 intensity exercise, respectively) and summed for a total leisure activity score.(19,20) A score of  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  $\geq 24$  indicates an active lifestyle, a score of 14-23 indicates a moderately active lifestyle, and a  
4 score of  $< 14$  indicates an insufficiently active/sedentary lifestyle.(19) Participants with a history  
5 of infection are asked to report the number of times they exercised in each category before and  
6 after their COVID-19 illness; participants without a history of infection are asked in reference to  
7 before and after the COVID-19 pandemic.  
8  
9  
10

### 11 12 Sleep Quality

13  
14 Sleep quality is assessed using questions adapted from the AIDS Linked to the IntraVenous  
15 Experience (ALIVE) Study and the Idiopathic Hypersomnia Severity Scale. The ALIVE study is a  
16 prospective cohort study designed to characterize the incidence and natural history of HIV  
17 infection among injection drug users in Baltimore, MD.(22) Participants are asked how often  
18 they experience a list of five items related to sleep quality over the past four weeks. For each  
19 item, participants respond based on the following scale: 1 (all of the time), 2 (most of the time),  
20 3 (a good bit of the time), 4 (some of the time), 5 (a little bit of the time), or 6 (none of the time).  
21  
22

23  
24 The Idiopathic Hypersomnia Severity Scale (IHHS) was validated for use in patients  
25 experiencing three major symptoms of idiopathic hypersomnia: excessive daytime sleepiness,  
26 prolonged nighttime sleep, and sleep inertia, and was found to have high internal consistency  
27 (Cronbach  $\alpha = .89$ ) and good content validity.(23,24) The scale consists of 14 items and each  
28 item is scored separately and then summed together for a total score ranging from 0-50. Higher  
29 scores represent more severe/frequent symptoms of idiopathic hypersomnia.(23,24) For the  
30 purpose of the JHCLS, researchers utilized four questions from the IHHS for a range of scores  
31 from 0-14.  
32  
33  
34  
35  
36  
37

### 38 39 Mental Fatigue

40  
41 Mental fatigue is assessed using the Wood Mental Fatigue Inventory (WMFI). The WMFI  
42 has been validated for use in patients with Myalgic Encephalomyelitis/Chronic Fatigue  
43 Syndrome (ME/CFS) and was found to have high internal consistency (Cronbach  $\alpha = .93$ ) and  
44 good test-retest reliability (Pearson's  $r = 0.887$ ). (25) Participants are asked how much they have  
45 been bothered by a list of nine items over the past two weeks. Each item is scored on the  
46 following scale: 0 (not at all), 1 (a little), 2 (somewhat), 3 (quite a lot), or 4 (very much). At the  
47 end of the assessment, the scores are summed together for a range of 0-36. Higher scores  
48 indicate greater levels of mental fatigue.(25)  
49  
50  
51  
52  
53

### 54 55 Anxiety

1  
2  
3 To assess anxiety, researchers utilize the Generalized Anxiety Disorder-7 (GAD-7). The  
4 GAD-7 has been validated for use in the general population and was found to have both high  
5 internal consistency (Cronbach  $\alpha = .92$ ) and good criterion, construct, factorial, and procedural  
6 validity.(26) Participants are asked how often they have been bothered by a list of seven items  
7 over the past two weeks. For each item, participants are scored based on the following scale: 0  
8 (not at all), 1 (several days), 2 (more than half the days), or 3 (nearly every day). At the end of  
9 the assessment, the scores are summed together for a range of 0-21. A score of 0-4 indicates  
10 no anxiety disorder, a score of 5-9 indicates a mild anxiety disorder, a score of 10-14 indicates a  
11 moderate anxiety disorder, and a score of  $\geq 15$  indicates a severe anxiety disorder.(26)  
12  
13  
14  
15  
16  
17

## 18 Demographics

19  
20 Researchers self-designed survey questions to obtain demographic information, including  
21 gender, race/ethnicity, country of residence, year of birth, educational attainment, work activities  
22 prior to the COVID-19 pandemic, primary occupation, total household income, and total number  
23 of dependents.  
24  
25  
26

## 27 Patient and public involvement

28  
29 There was no patient or public involvement in the design, conduct, reporting, or  
30 dissemination plans of our research. However, patient feedback is routinely discussed and  
31 considered. Specifically, patients are encouraged to reach out to study team members with  
32 suggestions on ways to improve the survey and the survey has been adjusted several times  
33 based on patient suggestions. In addition, study findings are regularly disseminated to patients  
34 via quarterly study newsletters posted on the study website ([www.covid-long.com](http://www.covid-long.com)).  
35  
36  
37  
38  
39

## 40 Baseline characteristics of JHCLS participants

41 Among 16,764 participants with a history of SARS-CoV-2 infection and defined long COVID  
42 status, the median age was 43 years, 84% were female, 88% self-reported white race, and  
43 8.0% self-reported Hispanic/Latino ethnicity (Table 1). In terms of socioeconomic status, 70% of  
44 participants self-reported a bachelor's degree or higher and 72% self-reported an annual  
45 household income of greater than or equal to \$50,000. A diverse array of self-reported pre-  
46 existing comorbid conditions were reported, including hypertension (15%),  
47 depression/anxiety/other mental health conditions (35%), asthma/reactive airway  
48 disease/chronic lung disease (16%), and autoimmune disorders (9.6%) (Table 2). In addition,  
49 the majority of participants (65%) were classified as overweight/obese based on a calculated  
50 BMI of  $\geq 25$ .  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 Prior to COVID-19 illness, 75% of participants reported very good/excellent health status  
4 and 8.2% of participants reported fair/poor health status (Table 2). During the acute phase of  
5 COVID-19 illness, 99% of participants reported experiencing at least one symptom. Of those,  
6 90% reported cardiopulmonary symptoms (e.g., new/worsening cough, shortness of breath,  
7 rapid heart rate), 89% reported systemic symptoms (e.g., fatigue, muscle weakness, fever),  
8 85% reported neuropsychiatric symptoms (e.g., headache, dizziness, neuropathy), and 55%  
9 reported gastrointestinal symptoms (e.g., vomiting, diarrhea, lack of appetite). Overall, 9.9% of  
10 participants self-reported being hospitalized for their COVID-19 illness and 63% were defined as  
11 having long COVID based on the WHO definition.  
12

13  
14 At the time of study enrollment, 39% of participants with a history of infection reported not  
15 being vaccinated against SARS-CoV-2 compared to 56% who reported receiving at least a  
16 complete first vaccination series (Table 2). The median number of days between initial SARS-  
17 CoV-2 infection and study enrollment was 173 days. While most participants reported  
18 experiencing their initial SARS-CoV-2 infection in 2020 (56%), 29% reported being infected in  
19 2021, and 16% reported being infected in 2022.  
20

21  
22 Similar characteristics were found in participants without a history of SARS-CoV-2 infection  
23 who completed the baseline survey. Among 799 participants, the median age was 42, 85%  
24 were female, 82% self-reported white race, and 5.9% self-reported Hispanic/Latino ethnicity  
25 (Table 1). A higher percentage of participants without a history of infection self-reported 'other'  
26 race (13% compared to 5.4%) which was largely due to a greater number self-reporting  
27 Asian/Pacific Islander/Native Hawaiian race. With regard to socioeconomic status, a higher  
28 percentage of participants without a history of infection reported a bachelor's degree or higher  
29 (84% compared to 70%) and 72% reported an annual household income of \$50,000 or more.  
30 Comparable pre-existing comorbid conditions were reported: hypertension (13%),  
31 depression/anxiety/other mental health conditions (36%), asthma/reactive airway  
32 disease/chronic lung disease (12%), and autoimmune disorders (8.1%) (Table 2). Based on  
33 calculated BMI, a slightly higher percentage of participants without a history of infection were  
34 classified as having a normal BMI (43% compared to 34%).  
35

36  
37 Of participants without a history of SARS-CoV-2 infection, 75% reported very good/excellent  
38 health status and 7.5% reported fair/poor health status prior to the COVID-19 pandemic (Table  
39 2). At time of study enrollment, a higher percentage of participants without a history of infection  
40 reported at least a complete first vaccination series (97% compared to 56%). It is worth noting  
41 that enrollment for participants without a history of infection opened up in March 2022 when  
42 vaccinations were more widely available, likely accounting for this difference.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

The demographic and clinical characteristics between those who agreed to be contacted for future studies and those who declined were comparable, with the exception of long COVID status (Supplementary Table 2). Unsurprisingly, more individuals who fully recovered declined continued participation in the study. However, the number of indeterminate individuals (too early to determine long COVID status) was similar.

**Table 1** Baseline demographic characteristics of United States participants in the Johns Hopkins COVID Long Study

	Study Sample with SARS-CoV-2 Infection: Baseline Data <sup>1,2,3</sup> (n = 16,764)	Study Sample without SARS-CoV-2 Infection: Baseline Data <sup>1,4</sup> (n = 799)
<b>Gender</b>		
Cisgender man	2,514 (15%)	104 (13%)
Cisgender woman	14,010 (84%)	674 (85%)
Transgender man	24 (0.1%)	2 (0.3%)
Transgender woman	14 (0.1%)	1 (0.1%)
Different identity	181 (1.1%)	16 (2.0%)
Missing	21	2
<b>Race</b>		
White	14,651 (88%)	651 (82%)
Black	489 (3.0%)	15 (1.9%)
Other	890 (5.4%)	100 (13%)
Mixed race	537 (3.2%)	24 (3.0%)
Missing	197	9
<b>Hispanic, Latino or Spanish origin</b>	1,323 (8.0%)	47 (5.9%)
Missing	122	5
<b>Median age, IQR</b>	43 (34,55)	42 (32,57)
Missing	45	3
<b>Educational attainment</b>		
High school, GED, or less	974 (5.8%)	30 (3.8%)
Some college, Associates/technical degree	4,150 (25%)	98 (12%)
Bachelor's degree	5,135 (31%)	241 (30%)
Post-graduate degree	6,461 (39%)	430 (54%)
Missing	44	0
<b>Annual household income</b>		
<\$25,000	1,588 (11%)	100 (14%)
\$25,000 - \$34,999	957 (6.7%)	42 (5.8%)
\$35,000 - \$49,999	1,486 (10%)	60 (8.3%)
\$50,000 - \$74,999	2,697 (19%)	118 (16%)
\$75,000 or greater	7,635 (53%)	405 (56%)
Missing	2,401	74
<b>Region</b>		
Northeast	3,159 (19%)	180 (23%)
Midwest	3,462 (21%)	141 (18%)
South	6,581 (39%)	281 (35%)
West	3,538 (21%)	197 (25%)
Missing	24	0

<sup>1</sup>Missing data were due to invalid data, “don’t know” responses, “refuse to answer” responses, and missing responses. Percentages do not add up to 100% due to missing data. The number of missing data varies due to participants dropping out of the survey at different sections.

<sup>2</sup>Baseline data in participants with a history of SARS-CoV-2 infection is as of October 20, 2022.

<sup>3</sup>Limited to participants with a defined long COVID status. Long COVID status was determined using the [WHO definition](#). 320 participants without a defined long COVID status were excluded: 283 provided an initial SARS-CoV-2 infection date before the first confirmed positive test in the United States (January 20, 2020), 28 provided an invalid SARS-CoV-2 infection date, nine did not provide a SARS-CoV-2 infection date nor report experiencing symptoms of COVID-19.

<sup>4</sup>Baseline data in participants without a history of SARS-CoV-2 infection is as of February 14, 2023.

**Table 2** Baseline clinical characteristics of United States participants in the Johns Hopkins COVID Long Study

	Study Sample with SARS-CoV-2 Infection: Baseline Data <sup>1,2</sup> (n = 16,764)	Study Sample without SARS-CoV-2 Infection: Baseline Data <sup>1,3</sup> (n = 799)
Body mass index (kg/m <sup>2</sup> )		
Underweight (<18.5)	285 (1.8%)	13 (1.6%)
Normal weight (18.5 – 24.9)	5,517 (34%)	342 (43%)
Overweight (25 – 29.9)	4,643 (29%)	216 (27%)
Obese (30 and above)	5,827 (36%)	225 (28%)
Missing	492	3
Comorbid conditions		
Diabetes	716 (4.4%)	32 (4.0%)
Cardiovascular disease/congestive heart failure	379 (2.3%)	24 (3.0%)
Hypertension	2,526 (15%)	105 (13%)
Chronic kidney disease	138 (0.8%)	6 (0.8%)
Cancer	392 (2.4%)	17 (2.1%)
Asthma/reactive airway disease/chronic lung disease	2,684 (16%)	99 (12%)
Overweight/obese	4,853 (30%)	187 (23%)
Autoimmune disorder	1,568 (9.6%)	65 (8.1%)
Stroke	116 (0.7%)	9 (1.1%)
Depression/anxiety/other mental health condition	5,730 (35%)	286 (36%)
Missing	388	0
Self-rated health status prior to COVID-19 <sup>4</sup>		
Excellent	6,297 (38%)	283 (35%)
Very good	6,192 (37%)	321 (40%)
Good	2,900 (17%)	135 (17%)
Fair	1,242 (7.4%)	53 (6.6%)
Poor	126 (0.8%)	7 (0.9%)
Missing	7	0
Vaccination status at time of enrollment		
None = 0	6,414 (39%)	22 (2.8%)
Partial vaccination	805 (4.9%)	4 (0.5%)
Complete first series	4,006 (24%)	93 (12%)
≥1 Booster	5,208 (32%)	679 (85%)
Missing	331	1
Timing of initial SARS-CoV-2 infection		
January - June 2020	3,804 (23%)	N/A
July - December 2020	5,484 (33%)	N/A
January - June 2021	2,216 (13%)	N/A
July - December 2021	2,629 (16%)	N/A
≥January 2022	2,631 (16%)	N/A

**Table 2** Baseline clinical characteristics of United States participants in the Johns Hopkins COVID Long Study

	Study Sample with SARS-CoV-2 Infection: Baseline Data <sup>1,2</sup> (n = 16,764)	Study Sample without SARS-CoV-2 Infection: Baseline Data <sup>1,3</sup> (n = 799)
Missing	0	N/A
Time between initial infection and survey completion in days (median (IQR))	173 (70,382)	N/A
Missing	0	N/A
Symptom status at initial COVID-19 illness		
Symptomatic	16,588 (99%)	N/A
Asymptomatic	175 (1.0%)	N/A
Missing	1	N/A
Presenting symptoms at initial COVID-19 illness		
Cardiopulmonary	15,140 (90%)	N/A
Neuropsychiatric	14,178 (85%)	N/A
Systemic	14,949 (89%)	N/A
Gastrointestinal	9,175 (55%)	N/A
Missing	0	N/A
Hospitalization status at initial COVID-19 illness		
Not hospitalized	14,839 (90%)	N/A
Hospitalized	1,627 (9.9%)	N/A
Missing	298	N/A
Long COVID status at survey completion <sup>5</sup>		
Has long COVID	10,518 (63%)	N/A
Does not have long COVID	1,246 (7.4%)	N/A
Cannot be determined <sup>6</sup>	5,000 (30%)	N/A

<sup>1</sup>Missing data were due to invalid data, “don’t know” responses, “refuse to answer” responses, and missing responses. Percentages do not add up to 100% due to missing data. The number of missing data varies due to participants dropping out of the survey at different sections.

<sup>2</sup>Baseline data in participants with a history of SARS-CoV-2 infection is as of October 20, 2022.

<sup>3</sup>Baseline data in participants without a history of SARS-CoV-2 infection is as of February 14, 2023.

<sup>4</sup>Participants with a history of SARS-CoV-2 infection were asked for self-rated health status prior to their COVID-19 illness. Participants without a history of SARS-CoV-2 infection were asked for self-rated health status prior to the COVID-19 pandemic.

<sup>5</sup>Limited to participants with a defined long COVID status. Long COVID status was determined using the [WHO definition](#). 320 participants without a defined long COVID status were excluded: 283 provided an initial SARS-CoV-2 infection date before the first confirmed positive test in the United States (January 20, 2020), 28 provided an invalid SARS-CoV-2 infection date, nine did not provide a SARS-CoV-2 infection date nor report experiencing symptoms of COVID-19.

<sup>6</sup>Long COVID status could not be determined because fewer than 12 weeks existed between initial SARS-CoV-2 infection and survey completion.

## STRENGTHS AND LIMITATIONS

The JHCLS is a large, online, prospective cohort study of adults with representation in 53 U.S. states and territories. The baseline survey collects comprehensive clinical and behavioral data, including data related to COVID-19 diagnosis and treatment, health history, pre-existing health conditions, and physical, mental, and cognitive limitations, and utilizes several reliable,

1  
2  
3 validated scales to assess outcomes and exploratory variables. Participants are given the option  
4 to complete a one-time, anonymous online survey or to consent to longitudinal follow-up at  
5 predefined time intervals (every 3-6 months). In addition, the overall participant burden is  
6 minimal.  
7  
8

9 A major strength of the JHCLS is that a positive SARS-CoV-2 test is not required to be  
10 eligible to participate. We recognize that testing is often limited or inaccessible, and thus require  
11 either a self-reported positive test or symptoms of COVID-19. In addition, our survey collects  
12 data on a wide range of organ systems using several different validated measures. Despite  
13 early studies focusing primarily on the respiratory symptoms associated with initial COVID-19  
14 illness (e.g., shortness of breath), we appreciate that the SARS-CoV-2 virus may have notable  
15 effects on other organ systems following the acute period of infection as well.  
16  
17  
18  
19

20 Another strength of the JHCLS is the inclusion of participants without a history of SARS-  
21 CoV-2 infection which provides a natural control group, while also allowing for the determination  
22 of the incidence of long COVID among those who report a SARS-CoV-2 infection during follow-  
23 up. Importantly, both samples are comparable in terms of sociodemographic variables and pre-  
24 existing health conditions. We also recognize that many of the heterogeneous symptoms  
25 reported as long COVID may reflect all of us collectively living through a pandemic (i.e., anxiety,  
26 depression). Thus, it is important that we compare those with and without infection to evaluate  
27 some of these outcomes during the same time frame (versus retrospective or historical  
28 controls).  
29  
30  
31  
32  
33

34 In addition, there are few longitudinal studies focused on post-acute outcomes of COVID-19.  
35 Longitudinal studies provide an opportunity to evaluate change over time in exposures and  
36 outcomes. The longitudinal collection of data on new/continuing COVID-19 symptoms at each  
37 time point during follow-up will allow for evaluation of resolution and persistence of symptoms  
38 over time, as well as the impact of re-infection, vaccination, and other health changes. To date,  
39 just under 7,000 participants have consented to participate in longitudinal follow-up and have  
40 completed their first follow-up survey.  
41  
42  
43  
44  
45

46 The JHCLS also has a few limitations. The reliance on self-reported clinical data, including  
47 self-reported SARS-CoV-2 tests, may result in recall and measurement bias. Although a  
48 confirmed SARS-CoV-2 test would be preferable, we recognize that tests were not available to  
49 everyone and that restriction to only those with a confirmed test would introduce selection bias.  
50 A second limitation is the possibility of selection bias due to the fact that the survey must be  
51 completed using a smart device or computer with internet access. This may preclude  
52 participants from lower socioeconomic statuses from participating. There is also a risk that  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 findings from the JHCLS are not generalizable as the majority of participants self-reported white  
4 race, female gender, and are from a higher socioeconomic status. To address this, we plan to  
5 do stratified-specific analyses that may be better representative of individuals within that same  
6 stratum. However, whether a study is representative or not depends not on demographics but  
7 on potential effect measure modifiers that may or may not include demographics.(27)  
8 Additionally, results that may not necessarily be generalizable in the effect estimate may still be  
9 generalizable in the direction of effect (e.g., protective or increased risk) of an exposure on  
10 outcome.(27)  
11  
12  
13  
14  
15

16 Additionally, many individuals enroll many months after their acute infection when they  
17 already have long COVID. A potential selection bias would include increased likelihood of  
18 participation among those with more severe long COVID. However, it is important to note that  
19 the JHCLS has a subset of individuals (n = 2,020) who enrolled during their acute infection  
20 (within four weeks of infection). The high percentage of participants in our study with long  
21 COVID (63%) also likely reflects a selection bias on those willing to participate in COVID-19  
22 research. However, those with and without a history of SARS-CoV-2 infection are similar in their  
23 demographic characteristics (Table 1). Another limitation is the possibility of recall bias,  
24 especially among participants with a history of COVID-19 illness experiencing mental fatigue  
25 and/or other cognitive limitations at the time of survey completion.  
26  
27  
28  
29  
30  
31

32 A final limitation is the use of non-validated instruments to collect COVID-19 related data,  
33 including COVID-19 diagnosis, treatments, and symptoms. We were limited by the unavailability  
34 of validated instruments to capture these domains at the time of study initiation. However, when  
35 available, we used validated instruments that targeted several specific domains (e.g., anxiety,  
36 mental fatigue, etc.), and when unavailable, we drew upon experience and validated  
37 instruments developed for other infectious diseases to develop questions used by our group and  
38 others across multiple COVID-19 studies.  
39  
40  
41  
42  
43

#### 44 **Future plans**

45 Moving forward, the JHCLS will continue to enroll additional participants with and without a  
46 history of SARS-CoV-2 infection and collect data from the baseline and longitudinal surveys.  
47 The study team is in the initial stages of analyzing the longitudinal data collected thus far,  
48 focusing on the progression and resolution of long COVID symptoms over time. In addition, the  
49 study team is planning a cluster analysis of both initial and new/continuing COVID-19 symptoms  
50 to help address the broad WHO definition of long COVID. We plan to do this by bringing  
51 together the rich symptom data we have in our study with data on the impact each reported  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 symptom has on daily functioning. In the future, the study team may apply for funding to answer  
4 additional research questions and to continue following the longitudinal participants for a longer  
5 period of time.  
6  
7

8 The JHCLS has the potential to impact both our overall understanding of long COVID and  
9 our ability to identify subgroups of individuals for targeted interventions. We can also capture  
10 real-time changes by SARS-CoV-2 variants (based on calendar time), location (using geospatial  
11 data), birth/age cohorts, and/or vaccine data.  
12  
13  
14  
15

## 16 **COLLABORATION**

17 The JHCLS invites researchers to contact the corresponding author for collaboration  
18 opportunities.  
19  
20  
21

## 22 **Acknowledgements**

23 We would like to express our deepest appreciation to our participants for their dedication,  
24 unwavering commitment, and vulnerability in sharing their stories with us. We would also like to  
25 thank the REDCap team at the Johns Hopkins Bloomberg School of Public Health for their  
26 continued assistance and guidance. This endeavor would not have been possible without their  
27 help. Lastly, we'd like to acknowledge and thank our student researchers.  
28  
29  
30  
31  
32

## 33 **Author contributions**

34 B. Lau, P. Duggal, and S.H. Mehta conceived the original study concept and design and act  
35 as Co-Principal Investigators. They take responsibility for the integrity of the data. B. Lau, P.  
36 Duggal, S.H. Mehta, and E. Wentz were responsible for the acquisition of the data. E. Wentz  
37 prepared the first draft of this manuscript, under the supervision of B. Lau, P. Duggal, and S.H.  
38 Mehta. E. Wentz, Z. Ni, K. Yenokyan, C. Vergara, J. Pahwa, T. Kammerling, P. Xiao, P. Duggal,  
39 B. Lau, and S.H. Mehta were involved in reviewing the manuscript and contributing to critical  
40 revisions. Administrative and technical support was provided by E. Wentz, C. Vergara, Z. Ni, J.  
41 Pahwa, T. Kammerling, and P. Xiao.  
42  
43  
44  
45  
46  
47

## 48 **Funding**

49 The study is supported by the Johns Hopkins University COVID-19 Research Response  
50 Program (N/A) and in part by the Johns Hopkins University Center for AIDS Research  
51 (P30AI094189), which is supported by the following NIH Co-Funding and Participating Institutes  
52 and Centers: NIAID, NCI, NICHD, NHLBI, NIDA, NIA, NIGMS, NIDDK, NIMHD. The content is  
53 solely the responsibility of the authors and does not necessarily represent the official views of  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 the NIH.  
4  
5

### 6 **Competing interests**

7 S.H. Mehta receives materials support from Abbott Laboratories (not related to this study).  
8  
9

### 10 **Patient consent for publication**

11 Not applicable.  
12  
13

### 14 **Ethics approval**

15  
16 The study protocol was approved and exempted by the Institutional Review Board at the  
17 Johns Hopkins Bloomberg School of Public Health (IRB00014874) on January 8, 2021.  
18  
19

### 20 **Data sharing statement**

21 Not applicable.  
22  
23

### 24 **Figure 1 legend**


25 Participants who agree to be contacted for future studies are asked to consider joining the  
26 longitudinal follow-up cohort 3-6 months after they complete the baseline survey. As of this  
27 report, not everyone who has agreed to be contacted for future studies has been invited to join  
28 the longitudinal follow-up cohort.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## REFERENCES

1. Bourmistrova NW, Solomon T, Braude P, Strawbridge R, Carter B. Long-term effects of COVID-19 on mental health: A systematic review. *J Affect Disord*. 2022 Feb;299:118–25.
2. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. *Nat Med*. 2021 Apr;27(4):601–15.
3. Raman B, Bluemke DA, Lüscher TF, Neubauer S. Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. *Eur Heart J*. 2022 Mar 14;43(11):1157–72.
4. Montani D, Savale L, Noel N, Meyrignac O, Colle R, Gasnier M, et al. Post-acute COVID-19 syndrome. *Eur Respir Rev*. 2022 Mar 31;31(163):210185.
5. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. *Lancet Infect Dis*. 2022 Apr;22(4):e102–7.
6. Perlis RH, Santillana M, Ognyanova K, Safarpour A, Lunz Trujillo K, Simonson MD, et al. Prevalence and Correlates of Long COVID Symptoms Among US Adults. *JAMA Netw Open*. 2022 Oct 27;5(10):e2238804.
7. Van Kessel SAM, Olde Hartman TC, Lucassen PLBJ, Van Jaarsveld CHM. Post-acute and long-COVID-19 symptoms in patients with mild diseases: a systematic review. *Fam Pract*. 2022 Jan 19;39(1):159–67.
8. Domingo FR, Waddell LA, Cheung AM, Cooper CL, Belcourt VJ, Zuckermann AME, et al. Prevalence of long-term effects in individuals diagnosed with COVID-19: an updated living systematic review [Internet]. *Epidemiology*; 2021 Jun [cited 2023 Jun 28]. Available from: <http://medrxiv.org/lookup/doi/10.1101/2021.06.03.21258317>
9. Castanares-Zapatero D, Chalon P, Kohn L, Dauvrin M, Detollenaere J, Maertens De Noordhout C, et al. Pathophysiology and mechanism of long COVID: a comprehensive review. *Ann Med*. 2022 Dec 31;54(1):1473–87.
10. Rodriguez-Sanchez I, Rodriguez-Mañas L, Laosa O. Long COVID-19: The Need for an Interdisciplinary Approach. *Clin Geriatr Med*. 2022 Aug;38(3):533–44.
11. Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. *Nat Med*. 2022 May;28(5):911–23.
12. Ramakrishnan RK, Kashour T, Hamid Q, Halwani R, Tleyjeh IM. Unraveling the Mystery Surrounding Post-Acute Sequelae of COVID-19. *Front Immunol*. 2021 Jun 30;12:686029.
13. Pavli A, Theodoridou M, Maltezou HC. Post-COVID Syndrome: Incidence, Clinical Spectrum, and Challenges for Primary Healthcare Professionals. *Arch Med Res*. 2021 Aug;52(6):575–81.
14. Karuna S, Gallardo-Cartagena JA, Theodore D, Hunidzarira P, Montenegro-Idrogo J, Hu J, et al. Post-COVID symptom profiles and duration in a global convalescent COVID-19 observational cohort: Correlations with demographics, medical history, acute COVID-19 severity and global region. *J Glob Health*. 2023 Jun 23;13:06020.

15. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform.* 2009 Apr;42(2):377–81.
16. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: Building an international community of software platform partners. *J Biomed Inform.* 2019 Jul;95:103208.
17. Ferrucci L. The Baltimore Longitudinal Study of Aging (BLSA): a 50-year-long journey and plans for the future. *J Gerontol A Biol Sci Med Sci.* 2008 Dec;63(12):1416–9.
18. Stone JL, Norris AH. Activities and Attitudes of Participants in the Baltimore Longitudinal Study. *J Gerontol.* 1966 Oct 1;21(4):575–80.
19. Gaston Godin. The Godin--Shephard Leisure--Time Physical Activity Questionnaire. *Health Fit J Can.* 2011;4(1):18–22.
20. Godin G, Shephard RJ. A simple method to assess exercise behavior in the community. *Can J Appl Sport Sci J Can Sci Appl Au Sport.* 1985 Sep;10(3):141–6.
21. Amireault S, Godin G. The Godin-Shephard Leisure-Time Physical Activity Questionnaire: Validity Evidence Supporting its Use for Classifying Healthy Adults into Active and Insufficiently Active Categories. *Percept Mot Skills.* 2015 Apr;120(2):604–22.
22. Vlahov D, Anthony JC, Munoz A, Margolick J, Nelson KE, Celentano DD, et al. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. *NIDA Res Monogr.* 1991;109:75–100.
23. Rassu AL, Evangelista E, Barateau L, Chenini S, Lopez R, Jaussent I, et al. Idiopathic Hypersomnia Severity Scale to better quantify symptoms severity and their consequences in idiopathic hypersomnia. *J Clin Sleep Med.* 2022 Feb;18(2):617–29.
24. Dauvilliers Y, Evangelista E, Barateau L, Lopez R, Chenini S, Delbos C, et al. Measurement of symptoms in idiopathic hypersomnia: The Idiopathic Hypersomnia Severity Scale. *Neurology.* 2019 Apr 9;92(15):e1754–62.
25. Bentall RP, Wood GC, Marrinan T, Deans C, Edwards RHT. A brief mental fatigue questionnaire. *Br J Clin Psychol.* 1993 Sep;32(3):375–7.
26. Spitzer RL, Kroenke K, Williams JBW, Löwe B. A Brief Measure for Assessing Generalized Anxiety Disorder: The GAD-7. *Arch Intern Med.* 2006 May 22;166(10):1092.
27. Jacqueline E Rudolph, Yongqi Zhong, Priya Duggal, Shruti H Mehta, Bryan Lau. Defining representativeness of study samples in medical and population health research. *BMJ Med.* 2023 May 1;2(1):e000399.



Caption : Participants who agree to be contacted for future studies are asked to consider joining the longitudinal follow-up cohort 3-6 months after they complete the baseline survey. As of this report, not everyone who has agreed to be contacted for future studies has been invited to join the longitudinal follow-up cohort.

189x231mm (300 x 300 DPI)

**Supplementary Table 1** Survey measures

Domain	Questionnaire	Variable Description	Validation	Scoring
SARS-CoV-2 Testing and COVID-19 Symptoms	Self-designed	General health before COVID-19 illness (population with history of SARS-CoV-2 infection) or COVID-19 pandemic (population without history of SARS-CoV-2 infection), SARS-CoV-2 testing (number of times, result, exposure, test type, month/year of first positive test), month/year of initial symptom onset, symptoms experienced during initial illness, new/continuing symptoms experienced after initial illness, impact of each symptom on daily activities, self-reported recovery compared to before COVID-19 illness (population with history of SARS-CoV-2 infection) or COVID-19 pandemic (population without history of SARS-CoV-2 infection), new physician diagnoses since COVID-19 illness (population with history of SARS-CoV-2 infection) or COVID-19 pandemic (population without history of SARS-CoV-2 infection)	N/A	Categorical responses
Vaccines and SARS-CoV-2 Re-infection	Self-designed	Flu vaccine uptake, COVID-19 vaccine uptake (number of doses, series type, month/year per dose), SARS-CoV-2 antibody testing (month/year of testing, result), COVID-19 treatment trials, COVID-19 re-infection (number of times, exposure, test type, month/year of each positive test, month/year of each symptom onset), comparison of first re-infection to initial infection	N/A	Categorical responses
COVID-19 Treatments and Hospitalizations	Self-designed	Treatments for COVID-19, treatments for new/continuing COVID-19 symptoms, hospitalizations (number of days, severity), health care utilization (pre-COVID-19 illness and current), health seeking behavior to treat symptoms	N/A	Categorical responses
Comorbidities	Self-designed	Self-reported current health status, pre-existing health conditions, cancer diagnosis (type, diagnosis timeframe, treatments), height, weight, current stress level, stress level before the COVID-19 pandemic	N/A	Categorical responses

<b>Supplementary Table 1</b> Continued				
<b>Domain</b>	<b>Questionnaire</b>	<b>Variable Description</b>	<b>Validation</b>	<b>Scoring</b>
Limitations and Exercise	Baltimore Longitudinal Study of Aging(17,18)	Overall physical limitations before COVID-19 illness (population with history of SARS-CoV-2 infection) or COVID-19 pandemic (population without history of SARS-CoV-2 infection), difficulty walking a quarter of a mile/one mile, difficulty walking up 10 steps/20 steps, difficulty with performing light housework/heavy housework, difficulty level (if difficulty reported), level of ease (if no difficulty reported), indicator for incident/prevalent disability	N/A	<p><u>Mobility disability</u>: Any level of difficulty walking a quarter of a mile</p> <p><u>Instrumental activities of daily living disability</u>: Any level of difficulty with light housework</p>
	Godin-Shephard Leisure-Time Physical Activity Questionnaire(19–21)	Number of times in a typical week doing strenuous, moderate, and mild intensity exercise for more than 15 minutes before and after COVID-19 illness (population with history of SARS-CoV-2 infection) or COVID-19 pandemic (population without history of SARS-CoV-2 infection)	<p>Validated in population of healthy adults</p> <p>Test-retest reliability: 0.94 for strenuous exercise, 0.46 for moderate exercise, and 0.48 for light exercise</p>	<p>1) Multiply number of times per week per category by Metabolic Equivalent of Task factor (3 for light, 5 for moderate, 9 for strenuous)</p> <p>2) Sum scores for total leisure time activity score</p> <ul style="list-style-type: none"> <li>• <math>\geq 24</math>: active lifestyle</li> <li>• 14-23: moderately active lifestyle</li> <li>• <math>&lt; 14</math>: sedentary lifestyle</li> </ul>
Sleep Quality	AIDS Linked to the IntraVenous Experience (ALIVE) Study(22)	Total hours slept in typical 24-hour period, overall sleep quality during last four weeks, insomnia (difficulty falling/staying asleep)	N/A	Categorical responses
	Idiopathic Hypersomnia Severity Scale(23,24)	Four indicators of hypersomnia (assessment of sleep adequacy, difficulty waking up, length of time to feel fully functioning upon waking, struggling to stay awake during the day)	<p>Validated in patients experiencing idiopathic hypersomnia</p> <p>High internal consistency (Cronbach <math>\alpha = .89</math>) and good content validity</p>	<p>1) Each item is assigned a score (0-3 or 0-4)</p> <p>2) Sum scores for a total of 0-14</p> <p>Higher scores represent more severe/frequent symptoms of idiopathic hypersomnia</p>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

<b>Supplementary Table 1</b> Continued				
<b>Domain</b>	<b>Questionnaire</b>	<b>Variable Description</b>	<b>Validation</b>	<b>Scoring</b>
Cognition	Wood Mental Fatigue Inventory (WMFI)(25)	Nine indicators of mental fatigue over last two weeks (confusion, mixed thoughts, poor concentration, difficulty with decision making, memory problems, issues taking things in, slow thoughts, muzzy head, issues finding words)	Validated in patients with ME/CFS  High internal consistency (Cronbach $\alpha$ =.93) and good test-retest reliability (Pearson's $r$ = 0.887)	1) Each item is assigned a score from 0-4  2) Sum scores for total of 0-36  Higher scores indicate greater levels of mental fatigue
Anxiety	Generalized Anxiety Disorder-7 (GAD-7)(26)	Seven indicators of anxiety over last two weeks (feeling anxious, not able to control worrying, worrying about different things, trouble relaxing, restlessness, irritability, feeling afraid)	Validated in general population  High internal consistency (Cronbach $\alpha$ =.92)  Good criterion, construct, factorial, and procedural validity	1) Each item is assigned a score from 0-3  2) Sum scores for total of 0-21  <ul style="list-style-type: none"> <li>• 0-4: no anxiety disorder</li> <li>• 5-9: mild anxiety disorder</li> <li>• 10-14: moderate anxiety disorder</li> <li>• <math>\geq</math>15: severe anxiety disorder</li> </ul>
Demographics	Self-designed	Work activities prior to the COVID-19 pandemic, primary occupation, household income in 2019, number of dependents	N/A	Categorical responses

**Supplementary Table 2** Comparison of baseline demographic and clinical characteristics among participants with SARS-CoV-2 infection who agreed and declined to be contacted for future studies<sup>1,2,3,4</sup>

	Agreed to be Contacted for Future Studies (n = 11,924)	Declined to be Contacted for Future Studies (n = 3,554)
<b>Gender</b>		
Cisgender man	1,829 (15%)	510 (14%)
Cisgender woman	9,934 (83%)	2,992 (84%)
Transgender man	15 (0.1%)	6 (0.2%)
Transgender woman	11 (0.1%)	1 (<0.1%)
Different identity	127 (1.1%)	36 (1.0%)
Missing	8	9
<b>Race</b>		
White	10,538 (89%)	3,067 (88%)
Black	348 (2.9%)	88 (2.5%)
Other	563 (4.8%)	213 (6.1%)
Mixed race	384 (3.3%)	117 (3.4%)
Missing	91	69
<b>Hispanic, Latino or Spanish origin</b>	892 (7.5%)	289 (8.2%)
Missing	68	35
<b>Median age, IQR</b>	46 (36,57)	42 (33,52)
Missing	34	6
<b>Educational attainment</b>		
High school, GED, or less	620 (5.2%)	243 (6.9%)
Some college, Associates/technical degree	3,009 (25%)	823 (23%)
Bachelor's degree	3,601 (30%)	1,116 (32%)
Post-graduate degree	4,676 (39%)	1,356 (38%)
Missing	18	16
<b>Annual household income</b>		
<\$25,000	1,163 (11%)	394 (13%)
\$25,000 - \$34,999	712 (6.5%)	227 (7.4%)
\$35,000 - \$49,999	1,125 (10%)	328 (11%)
\$50,000 - \$74,999	2,084 (19%)	576 (19%)
\$75,000 or greater	5,939 (54%)	1,540 (50%)
Missing	901	489
<b>Region</b>		
Northeast	2,216 (19%)	679 (19%)
Midwest	2,383 (20%)	810 (23%)
South	4,790 (40%)	1,290 (36%)
West	2,522 (21%)	766 (22%)
Missing	13	9
<b>Hospitalization status at initial COVID-19 illness</b>		
Not hospitalized	10,612 (89%)	3,305 (93%)
Hospitalized	1,304 (11%)	245 (6.9%)
Missing	8	4
<b>Comorbid conditions</b>		
Diabetes	561 (4.7%)	119 (3.4%)
Cardiovascular disease/congestive heart failure	287 (2.4%)	68 (1.9%)
Hypertension	1,930 (16%)	492 (14%)
Chronic kidney disease	97 (0.8%)	32 (0.9%)
Cancer	306 (2.6%)	71 (2.0%)
Asthma/reactive airway disease/chronic lung disease	2,077 (17%)	485 (14%)

**Supplementary Table 2** Comparison of baseline demographic and clinical characteristics among participants with SARS-CoV-2 infection who agreed and declined to be contacted for future studies<sup>1,2,3,4</sup>

	Agreed to be Contacted for Future Studies (n = 11,924)	Declined to be Contacted for Future Studies (n = 3,554)
Overweight/obese	3,670 (31%)	969 (27%)
Autoimmune disorder	1,203 (10%)	297 (8.4%)
Stroke	93 (0.8%)	14 (0.4%)
Depression/anxiety/other mental health condition	4,262 (36%)	1,171 (33%)
Missing	1	0
Long COVID status at survey completion		
Has long COVID	7,698 (65%)	2,069 (58%)
Does not have long COVID	693 (5.8%)	421 (12%)
Cannot be determined <sup>4</sup>	3,533 (30%)	1,064 (30%)

<sup>1</sup>Missing data were due to invalid data, “don’t know” responses, “refuse to answer” responses, and missing responses. Percentages do not add up to 100% due to missing data. The number of missing data varies due to participants dropping out of the survey at different sections.

<sup>2</sup>Baseline data in participants with a history of SARS-CoV-2 infection is as of October 20, 2022.

<sup>3</sup>Limited to participants with a defined long COVID status. Long COVID status was determined using the [WHO definition](#). 320 participants without a defined long COVID status were excluded: 283 provided an initial SARS-CoV-2 infection date before the first confirmed positive test in the United States (January 20, 2020), 28 provided an invalid SARS-CoV-2 infection date, nine did not provide a SARS-CoV-2 infection date nor report experiencing symptoms of COVID-19.

<sup>4</sup>Long COVID status could not be determined because fewer than 12 weeks existed between initial SARS-CoV-2 infection and survey completion.